The development and evaluation of small molecule-peptide conjugates as probes of prokaryotic ribosome exit tunnel-nascent peptide interaction by Washington, Arren Z.
THE DEVELOPMENT AND EVALUATION OF SMALL 
MOLECULE-PEPTIDE CONJUGATES AS PROBES OF 










Arren Zachary Washington 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 
School of Chemistry and Biochemistry 
 




Copyright © 2016 by Arren Z. Washington 
 
 
THE DEVELOPMENT AND EVALUATION OF SMALL 
MOLECULE-PEPTIDE CONJUGATES AS PROBES OF 





Approved by:   
   
Dr. Adegboyega K. Oyelere, Advisor 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 Dr. Stefan France 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
   
Dr. Charles Liotta 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 Dr. Steven Harvey 
Department of Biochemistry and 
Biophysics 
University of Pennsylvania 
   
Dr. Loren Williams 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
  
   





 First and foremost, I must express my gratitude to Dr. Adegboyega Oyelere.  
Without him and his guidance, the work presented here would not have been possible.  I 
am very grateful to have had an advisor with as much passion and insight to offer on a 
project such as this.  He not only taught me the laboratory skill set needed to achieve the 
goals, but also a way of thinking that will be beneficial in addressing any project in my 
future. 
 To my committee members: Drs. Loren Williams, Charles Liotta, Stefan France, 
and Steven Harvey.  I knew that I could always come to you should I need guidance or 
perspective.  My interactions with RiboEvo and its extended family helped shape the way 
I viewed aspects of this project on a larger scale. 
 To my lab members: Thank you for the support, guidance, and encouragement 
throughout my time here. 
 To those people that impacted my life while here: Dr. Anthony Baldridge, Dr. 
Josh Canzoneri, Dr. James Black, Dr. Pamela Pollet, Dean John Stein, Vice Provost 
Susan Cozzens, Associate Vice Provost Leslie Sharp, Robbie Brawner Ouzts, Dr. 
Subhasish Tapadar, and Yogi Patel.  In no small measure, each and every one of you 
helped me to either strive or survive, and sometimes both. 
 Next, I would like to thank my parents, Charlene and Jim Washington.  They have 
helped and supported me through countless struggles.  Some minor, others major.  Their 
faith in me never wavered.   Without their guidance and love over the years, I would 
 iv 
never have entered this phase of my life.  I love you both beyond words.  Thank you for 
everything you’ve taught me. 
 To my beautiful wife, Amanda, thank you for the patience, for the support and 
understanding, for loving me unconditionally.  I cannot wait for the next chapter of our 
life together to begin.  I love you, Angel. 
 Lastly, I would like to offer my truest thanks to all who were involved to make 




TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .............................................................................................. III 
LIST OF TABLES ......................................................................................................... VIII 
LIST OF SYMBOLS AND ABBREVIATIONS ............................................................. XI 
SUMMARY ................................................................................................................... XIV 
CHAPTER 1 INTRODUCTION .................................................................................. 1 
1.1 Prokaryotic Protein Translation .......................................................................... 1 
1.1.1 Biochemical Techniques: Small Molecule Probing ........................................ 2 
1.1.2 Crystallography ............................................................................................... 5 
1.2 Targeting the Prokaryotic Ribosome .................................................................. 8 
1.2.1 Antibiotics ....................................................................................................... 8 
1.2.2 Known Exit Tunnel Interacting Peptides ...................................................... 24 
1.3 Discussion ......................................................................................................... 31 
1.4 References ......................................................................................................... 32 
CHAPTER 2 DESIGN AND DEVELOPMENT OF SMALL MOLECULE PROBES 
TO ANALYZE RIBOSOME EXIT TUNNEL-NASCENT PEPTIDE INTERACTION 49 
2.1 Introduction ....................................................................................................... 49 
2.2 Puromycin ......................................................................................................... 50 
2.2.1 Synthesis of Puromycin-NMIA Coupled Anchor (3) ................................... 51 
2.2.2 Translation Inhibition.................................................................................... 51 
2.3 Linezolid ........................................................................................................... 53 
2.3.1 Design and Evaluation of Linezolid Classes ................................................ 53 
2.3.2 Synthesis of Linezolid Class Anchors and Probes 11 and 13 ....................... 57 
2.4 Telithromycin .................................................................................................... 60 
2.4.1 Design and Probe Synthesis .......................................................................... 61 
2.4.2 Peptolide Cell-Free Assay Evaluation .......................................................... 63 
2.4.3 Chemical Footprinting of E. coli 23S rRNA ................................................ 66 
2.4.4 Peptolide Cell-Free Assay Evaluation .......................................................... 68 
2.4.5 Biochemical Validation Through Crystallography ....................................... 72 
 vi 
2.4.6 Further Analyses of Peptolide-Induced Conformational Changes within the 
Exit Tunnel ................................................................................................................ 78 
2.5 Discussion ......................................................................................................... 82 
2.6 References ......................................................................................................... 83 
CHAPTER 3 DESIGN APPROACH TOWARD PEPTOLIDE PROBES WITH 
AFFINITY FOR THE L4/L22 CONSTRICTION SECTION TO THE EGRESS POINT 
AT THE BACK OF THE 50S SUBUNIT ........................................................................ 87 
3.1 Introduction ....................................................................................................... 87 
3.2 Azith-Trp Conjugate Design and Synthesis ...................................................... 90 
3.3 In Vitro Translation Inhibition Assay ............................................................... 91 
3.4 Antibacterial Activity........................................................................................ 95 
3.4.1 Protocol ......................................................................................................... 95 
3.4.2 Antibacterial Activity Results ....................................................................... 95 
3.5 Discussion ......................................................................................................... 97 
3.6 References ......................................................................................................... 98 
CHAPTER 4 REDESIGN OF CONJUGATE PROBES TO IMPROVE CELL 
MEMBRANE ACTIVITY.............................................................................................. 101 
4.1 Introduction ..................................................................................................... 101 
4.2 Whole Cell Activity of Linezolid-Inspired Anchors ...................................... 102 
4.3 Whole Cell Activity of Azithromycin-Inspired Anchors................................ 103 
4.4 Whole Cell Activity of Telithromycin-Inspired Anchors ............................... 105 
4.5 Replacement of the Peptide Moiety for Peptidiomimetic Peptoids ................ 107 
4.6 Discussion ....................................................................................................... 110 
4.7 References ....................................................................................................... 111 
CHAPTER 5 CONCLUSIONS AND FUTURE DIRECTIONS.............................. 112 
APPENDIX ..................................................................................................................... 115 
A.1. Chapter 2 Supplemental .................................................................................. 115 
A.1.1. Puromycin anchor characterization............................................................. 115 
A.1.2. Linezolid anchor class characterization ...................................................... 119 
A.2. Collaboration with Dr. Dev Arya of Clemson University .............................. 121 
A.2.1. Introduction ................................................................................................. 121 
 vii 
A.2.2. Manuscript Citation .................................................................................... 121 
A.2.3. Full data contribution .................................................................................. 122 
A.2.3.1. Prokaryotic Assay Results .................................................................. 122 





LIST OF TABLES 
Table 1:  IC50 cell free assays translation inhibition activity of peptolides against 
prokaryotic and eukaryotic ribosomal preparations. Luciferase activity was used as a 
reporter of translation inhibition in both systems. IC50 values were obtained from an 
average of three independent experiments. * No inhibition at maximum tested 
concentration (250 µM).  ** Maximum tested concentration increased 4-fold to 
obtain information about the extent of selectivity over RRL.  # Values determined 
by Dr. Joshua Canzoneri. ....................................................................................... 65 
Table 2:  IC50 and MIC50 data for compounds 19a-28a and 19b-28b.  All indole 
modifications studied are as shown.  S30 = E. coli cell free; RRL = rabbit 
reticulocyte cell free.  SA29213 = S. sureus ATCC 29213 (with serum as indicated). 
Enhancement is calculated as the ratio of MIC50 without serum over that with serum. 
ErmMRSA33591 = Erm
+
 MRSA ATCC 33591. EC27856 = E. coli ATCC 27856. nt 
= not tested. ............................................................................................................ 92 
Table 3:  Peptoid conjugate activity. .............................................................................. 109 
 
 ix 
LIST OF FIGURES 
Figure 1:  Small molecule probes. ................................................................................. 3 
Figure 2:  Base-specific (left) and sequence-independent (right) chemical probes. ...... 4 
Figure 3:  Example of Sanger Sequencing. .................................................................... 5 
Figure 4:  Haloarcula marismortui 50S: ....................................................................... 6 
Figure 5:  Neomycin bound to h44 ................................................................................ 9 
Figure 6:  Chloramphenicol Binding.  Top Structure of chloramphenicol.  Middle ...... 10 
Figure 7:  Clindamycin Binding.  Top Structure of clindamycin.  Bottom .................... 12 
Figure 8:  Shared binding sites....................................................................................... 13 
Figure 9:  Puromycin structure ...................................................................................... 15 
Figure 10:  Streptogramin A/B components .................................................................. 17 
Figure 11:  Linezolid Binding.  Top Structure of linezolid.  Bottom ............................. 19 
Figure 12:  Structures of representative examples of clinically useful macrolides. ...... 21 
Figure 13:  Telithromycin Binding.  Top Structure of telithromycin.  Bottom .............. 22 
Figure 14:  An overlay of major LSU-binding drug classes. ......................................... 23 
Figure 15:  Possible signal-relay pathways of Erm stalling. .......................................... 27 
Figure 16:  Synthesis of puromycin-inspired anchor. .................................................... 50 
Figure 17:  Synthesis of linezolid-inspired anchor. ....................................................... 53 
Figure 18:  Linezolid probes. ......................................................................................... 54 
Figure 19:  Synthesis of Probe 11. ................................................................................. 55 
Figure 20:  Synthesis of Probe 13. ................................................................................. 56 
Figure 21:  Telithromycin. ............................................................................................. 61 
Figure 22:  Peptolide final structures. ............................................................................ 62 
Figure 23:  DMS small molecule probing (A2058). ...................................................... 70 
Figure 24:  DMS small molecule probing (A752). ........................................................ 71 
Figure 25:  CMCT small molecule probing (U1963). ................................................... 72 
Figure 26:  Crystal Structure of peptolide 14c. .............................................................. 73 
 x 
Figure 27:  U1963 movement. ....................................................................................... 76 
Figure 28:  U1963 Adopted Base Pair. .......................................................................... 77 
Figure 29:  C790 Migration. .......................................................................................... 79 
Figure 30:  U2506 Migration. ........................................................................................ 80 
Figure 31:  U2585 Migration. ........................................................................................ 81 
Figure 32:  SecM Design. .............................................................................................. 88 
Figure 33:  Structures and MIC50s of linezolid-inspired conjugates.............................. 102 
Figure 34:  Structures and MIC50s of azithromycin-inspired conjugates. ..................... 104 
Figure 35:  Structures and MIC50s of second generation telithromycin-inspired 
conjugates. ............................................................................................................. 105 
Figure 36:  Standard Peptides and Peptoids. .................................................................. 108 
Figure 37:  Peptoid Conjugate. ...................................................................................... 110 






LIST OF SYMBOLS AND ABBREVIATIONS 
aa-tRNA Aminoacyl-tRNA 
CCA-pcb CCA-phenylalanine-caproic acid-biotin 
CMCT 
1- Cyclohexyl-(2-morpholinoethyl)carbodiimide metho-p-toluene 
sulfonate 
ddNTP Dideoxynucleotide triphosphate 
DEPC Diethyl pyrocarbonate 
DMS Dimethyl sulfate 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DTT Dithiothreitol 
EDCI N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
EDTA Ethylenediaminetetraacetic acid 
EF-G Elongation Factor – G 
EF-Tu Elongation Factor – Tu 
fMet Formyl methionine 
GTP Guanosine Triphosphate 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HOBT Hydroxybenzotriazole 
IF1/2/3 Initiation Factor 1/2/3 
LB Luria Bertani Broth 




MLSB Macrolide-lincosamide-streptogramin B 
mRNA Messenger RNA 
MRSA Methicillin-resistant Staphloccus aureus 
NMIA N-Methyl isatoic anhydride 
OD600 Optical Density, 600nm 
ORF Open reading frame 
PDB Protein Databank 
PrAMPs Proline-rich antimicrobial peptides 
PTC Peptidyl Transferase Center 
RAP Ribosome arrest peptide 
RNA Ribonucleic acid 
rProtein Ribosomal Protein 
RRF Ribosomal Recycling Factor 
RRL Rabbit reticulocyte 
rRNA Ribosomal RNA 
RT Reverse Transcription 
SD Sequence Shine Delgarno Sequence 
SDS Sodium dodecyl sulfate 
SHAPE Selective 2’-Hydroxyl Acylation analyzed by Primer Extension 
SSU Small Subunit, Ribosomal 
TBE Tris Borate EDTA buffer 
tRNA Transfer RNA 
 xiii 
TSB Tryptic Soy Broth 





As the knowledge base grows in regard to peptide synthesis and ribosomal 
actions, one facet of this is the extent and selectivity of interactions between the 
ribosomal exit tunnel and the nascent peptide.  Small molecule probing techniques have 
provided insight from binding locations of ribosomal targeting therapeutics as well as 
potential downstream conformational changes to regions of dynamic flexibility with more 
solvent exposure aiding in the determination of complex higher-order structures.  
Crystallography provided a means to explore atomic-level interactions.  This not only 
offered insight into potential questions and controversies posed by previous biochemical 
data, but also aided in the exploration and design of translation inhibiting antibiotics.  
However a means of more broadly probing the exit tunnel interactions without relying on 
mRNA and artificially stalling translation remained elusive.  The methodology presented 
within this document provides an approach to introduce a broad range of customizable 
peptide probes to discrete regions of the exit tunnel in a manner independent on 
translation.  Through the use of ribosomal large subunit targeting molecules (either 
clinically relevant or widely used mechanistic probes) as both delivery platforms as well 
as anchors, a means of presenting peptide sequences of various lengths and amino acid 
composition became possible.  Covalent modification of various anchor types offered the 
possibility of interaction scanning windows within the peptidyl transferase center and 
well into the ribosomal exit tunnel.  The successful presentation and evaluation of these 
small molecule-peptide conjugates provides an opportunity to identify regions of 
interaction within the exit tunnel while potentially displaying preference to amino acid 
types within these windows.  Through the use of four major anchor types, two clearly 
 xv 
rose to be viable while a third is continuing to show promise.  Probe-dependent 
interactions within the ribosome have been shown both biochemically and 
crystallographically strongly indicating that the methodology is not only viable, but a 
very attractive route of exploration for a region once thought to have little, if any, 
interaction with nascent peptides.  Biochemically, probes 14a-14h all show an orientation 
that projects the peptide moiety toward the peptidyl transferase center.  This is indicated 
through small molecule probing of the Escherichia coli ribosome and probe-dependent 
protection of U1963 of the large subunit 23S rRNA.  Crystallographic data collected of 
probe 14c within the Thermus thermophilus further confirmed this by providing atomic 
level detail of the peptide realigning over the macrolactone ring to project back toward 
the PTC.  This marks the first use of a translation-independent peptide probe resulting in 
substantial conformational change of multiple residues lining the exit tunnel.  Subsequent 
generations improved upon the design by seeking to project the peptide portion in a 
specific manner to expand the probing window.  Probes 19-28 sought to exploit a strong 
pi stack interaction existing within the SecM peptide sequence.  Within the SecM peptide 
sequence, tryptophan-155 engages in a pi stack with adenine-751, a 23S nucleotide that 
lines the wall of the prokaryotic ribosome exit tunnel further down the tunnel away from 
the PTC and macrolide binding site.  Successful engagement of this interaction would 
serve as a directional handle to encourage threading of the probe peptide selectively 
down the tunnel.  The collective observations taken from all probe classes as well as 
experimental opportunities therein spurred a new conjugate series.  Seeking to improve 
cell membrane activity in a step to improve whole cell activity of the conjugate probes, 
 xvi 
the peptide moiety was redesigned to incorporate membrane-active peptidomimetics that 




CHAPTER 1  INTRODUCTION   
1.1 Prokaryotic Protein Translation 
All cells, both prokaryotic and eukaryotic, are reliant on ribosomes for the 
synthesis of protein through the process of translation.  Prokaryotic ribosomes (70S) are 
made up of two subunits: the small subunit (30S) consists of a 16S ribosomal RNA 
(rRNA) sequence and over 20 ribo-proteins (rProteins) whereas the large subunit (50S) 
contains two rRNA sequences (23S and 5S) in addition to 30-40 rProteins.
1-5
  Translation 
is initiated upon complexation of the small subunit with the Shine-Delgarno sequence of 
messenger RNA (mRNA).  Initiation factors 1 and 3 (IF1, IF3) aid in proper codon-
anticodon pairing of fMet-tRNA (the initiator tRNA most seen in bacterial systems), 
while IF2-GTP coordinate the positioning of the charged end of fMET-tRNA in the 
ribosomal P-site.  Finally, the 50S large subunit caps this complex creating a functional 
70S ribosome.
6-12
  This complexation happens on the order of seconds whereas once in 
Elongation, the prokaryotic ribosome is capable of catalyzing the peptide bond formation 
at a rate of approximately 20 amino acids per second.
7
  Progression to the elongation 
phase is thought to be gated by IF2-bound GTP hydrolysis.
6
  Successful hydrolysis makes 
available the A-site for the first non-initiator tRNA shuttled by GTP-elongation factor Tu 
(EF-Tu).  Elongation continues through iterative rounds of tRNAs delivering appropriate 
amino acids as determined by codon:anticodon pairing between the mRNA and the stem 
loop of the tRNA, nucleophilic attack transferring the nascent chain to the A-site, and 
translocation of tRNAs in a ratcheting motion that is catalyzed by EF-G and GTP.  This 
translocation has been described as either a 2-3-2 (whereby the A-site vacancy is filled 
before E-site ejection) or a 2-1-2 (E-site ejection precedes A-site occupancy).
13
 
Translation is terminated once a stop codon is encountered.  This triggers hydrolysis and 
release of the nascent peptide as well as recycling of the ribosome subunits.   
 2 
 Peptide elongation occurs within the peptidyl transferase center (PTC).  It is 
within the PTC that the charged end of the aminoacyl-tRNA nucleophilically attacks the 
peptide chain bound to the P-site tRNA through an ester bond.  This ester bond is broken 
as the peptide transfers to the A-site tRNA, extending the protein by one amino acid.  
Translocation as described above shifts the A-site tRNA/protein complex to the P-site.  
As the protein continues to grow, it exits the PTC through the ribosomal exit tunnel.  This 
channel, approximately 80 Å long and 20 Å wide, cuts through the large subunit (LSU) 
and provides a pathway to extrude the nascent peptide.
14,15
  Once thought to be a passive 
conduit, there is growing support to suggest that the exit tunnel not only forms 
interactions but even regulates rates of translation of specific leader sequences thereby 
situationally stalling translation to allow the mRNA to adopt a secondary fold with 
another Shine-Delgarno sequence.  Examples of this, such as Erm class 
methyltransferases, are discussed in later sections.
16-18
 
1.1.1 Biochemical Techniques: Small Molecule Probing 
The current understanding of the process of translation has further revealed the versatility 
of the RNA in biology.  RNA is responsible for much of the architecture of the ribosome 
and aids in the decoding as seen with rRNA, carries genetic information through mRNA, 
and shuttles the necessary building blocks with tRNA.  Through all of these various 
functions, structural relationships and higher-level interactions are both complex and 
ordered.  Taking the ribosome as an example, the secondary and tertiary interactions of 
both RNA-RNA as well as RNA-protein maintain the complex structural fidelity.   
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Figure 1:  Small molecule probes.  A) Traditional, base-specific probing molecules.  
B) N-methyl isatoic anhydride (NMIA); reagent commonly used for SHAPE 
reactions.   
 
Toward understanding the complexity of these interactions, RNA probing became a 
highly practiced and refined field going back four decades with methods established to 
very broadly understand secondary structures to the very specific atomic level detail 
provided by chemical probes.
19-21
  Small molecules such as dimethyl sulfate (DMS), 1-
cyclohexyl-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate (CMCT), diethyl 
pyrocarbonate (DEPC), and kethoxal all generate adducts in a base-specific manner 
providing local structural information like base pairing and stacking (Fig. 1).  These 
modifications are predominately about the Watson-Crick face, allowing for adduct 
formation to be viewed as a function of solvent exposure at the hydrogen bonding face.  
Hydroxyl probing, alternatively, cleaves the phosphate backbone of solvent-exposed 
regions.  Newer generations of probing such as in-line probing and Selective 2’-Hydroxyl 
Acylation analyzed by Primer Extension (SHAPE) shine a light on regions of dynamic 
flexibility that are either ligand-induced or simply sites of low rigidity (Fig. 2).
22,23
  N-
methylisatoic anhydride (NMIA), a SHAPE reagent, is capable of being nucleophilically  
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Figure 2:  Base-specific (left) and sequence-independent (right) chemical probes.   
 
attacked by the 2’-OH of RNA ribose generating a modified adduct.  All small molecule 
adducts or fragments can then be visualized via electrophoretically separated cDNA 
products resulting from primer extension with reverse transcriptase (RT).  Orientation is 
achieved through Sanger sequencing where in-tandem RT experiments incorporating one 
of four chain-terminating dideoxynucleotide triphosphates (ddNTPs) lead to sequence 
data.  With the adduct formation at the ribose 3’-OH, progression by RT is halted 
resulting in a banding accumulation at the site of that specific ddNTP (Fig. 3).
24
 
While all of these probing techniques are powerful in their own right, a larger benefit 
comes from their combination and coupling with secondary structure folding 
predictions.
25,26
  By incorporating experimental data, confidence in the folding prediction 
increases greatly.  As demonstrated by Weeks, et al., the inclusion of traditional, base-




Figure 3:  Example of Sanger Sequencing.   
 
unconstrained 46% predictive accuracy when looking at E. coli 16S rRNA.  They, then, 
showed an additional increase to 95% using SHAPE reactivity to constrain other key 
regions.  This marriage of wet lab results and in silico predictions has changed the way 
nucleic acid probing is performed.  However, another method of visualizing higher order 
interactions has a different series of benefits. 
1.1.2 Crystallography 
Nearly concurrent with these strides in nucleic acid probing, ribosomal crystallography 
was advancing as fast as modern software, analytics, and technology would allow.  
Initially plagued by poor crystals, the selection of a more suitably robust organism 
increased the possibility of crystal growth and improved imaging through increased 
tolerance of the harsh conditions required for crystal formation.  These heartier ribosomes 
allowed for increased crystal populations permitting more successful diffraction.  
Preliminary low resolution success with Bacillus stearothermophilus
28
 improved by 
selecting the heartier Haloarcula marismortui
29
 which resulted in high resolution  
 6 
  
Figure 4:  Haloarcula marismortui 50S: Improvements in data collection and 
analysis allowed for increased resolution in ribosomal crystallography.  Left: PDB 
1FFK.  One of the first electron density maps, however many regions of high 
variability did not resolve.  Right: PDB 3I56.  Use of additional techniques provide 
more complete pictures of LSU, especially protein incorporation. 
 
diffraction in 1991.  Improved organism selection along with continued refinement 
finally allowed diffraction patterns to be solved below 3 Å resolution for 30S, and even 
past 6 Å for the whole 70S ribosome.
30-32
   
Iterative experimental improvements moved in tandem with data collection and 
interpretation.  A daunting complication demonstrating this was finding a way to prevent 
the deterioration of this 2.8 MDa biomolecule believed to be a result of the harsh 
conditions inherent to synchrotron irradiation.
33 
 Major methodology advances in the mid 
to late 1980s helped preserve the integrity of crystalized ribosomes through cryogenic 
temperatures during data collection.
34,35
  Continued advancement in data generation and 
collection exposed the next major technical problem of data interpretation.  The complex 
diffraction patterns generated could not be interpreted without better ways to solve the 
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phasing issue.  These diffraction patterns started to take form in 1998 as the use of 
molecular replacement and heavy atom clusters
36
 provided footholds to a 9 Å electron 
density map of H. marismortui 50S (Fig. 4).
32
  Continuing to improve on past results, 
electron density maps became more refined at resolutions better than 3.5 Å with more 
complexity.  The community was getting ever clearer glimpses of mRNA and various 
tRNAs bound to complete 70S.
37
  The culmination of these collective advances resulted 
in not just a tremendous foundation for future generations of researchers across multiple 
fields, but also in the awarding of the 2009 Nobel Prize in Chemistry to Vankatraman 
Ramakrishnan, Thomas A. Steitz, and Ada E. Yonath for the pioneering work that 
brought about the field of ribosomal crystallography.
38-40
 
Utilizing these new techniques finally provided for the opportunity to solve high 
resolution structures of ribosomes at an accelerated pace.  The proverbial flood gate had 
opened and outstanding questions now had methodology in place to be answered.  
Among these were establishing a better understanding for the mechanism of action for 
both clinically relevant and probing small molecules.  Within a year of those seminal 
crystal structure publications, crystals containing antibiotics became of utmost 
importance with each group listed above and others worldwide solving multiple 
structures with synthetic variants of biologically relevant factors or varied ribosome-
targeting classes of antibiotics. 
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1.2 Targeting the Prokaryotic Ribosome 
1.2.1 Antibiotics 
Antibiotics are collectively a broad category of small molecules that are either 
naturally synthesized for defense by various organisms or modified in a laboratory to 
increase clinical viability.  The bactericidal activity comes from the molecules’ abilities 
to inhibit many biological properties such as cell wall synthesis, DNA replication, or 
translation.  As this thesis revolves around ribosomal activity and interactions, emphasis 
will be placed on translation inhibitors with further emphasis on the large subunit (LSU) 
binders.  While biochemical information collected since the 1960s utilizing the probing 
techniques discussed previously was able to suggest targets, validation through 
crystallography was lacking.
41
  A great undertaking changed this as multiple research 
groups dedicated efforts to cocrystalizing various ribosomes with a vast array of 
antibiotics.  This new information provided a level of understanding that not only 
afforded interaction mapping, but brought about the possibility to improve upon drug 
design for progressive generations of compound classes.   
 Within the small subunit, aminoglycosides bind to the key structural element helix 
44 (h44) (Fig. 5).  They inhibit translation by interfering with decoding leading to 
aberrant proteins including the potential to slip past the stop codon.
42-44
  By stabilizing 
the nucleotides that monitor codon:anticodon interactions, near-cognate tRNAs become 
accepted with incorrect amino acid incorporation resulting.  Recently, the Arya lab has 
developed methods for rapid synthesis and a multi-assay screening of a vast library 
neomycin-amino acid conjugates to evaluate the effects of charge and sterics on optimal 
binding and activity.
45
  Tetracycline, a planar fused-ring system with a hydrophobic face  
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Figure 5:  Neomycin bound to h44 analog with universally conserved A1492/3 
bumped out (PDB 2A04).   
 
opposite a hydrophilic edge, is a widely prescribed broad-spectrum antibiotic that acts 
primarily by sterically hindering the entrance of the A-site tRNA.
46-48
  A third target 
within small subunit binders prevents the initiation complex from forming.  Examples of 
these include potent universal translation inhibitors edeine and pactamycin that both lead 




The large subunit also contains regions of high conservation that are targets of 
therapeutic targets.  The small molecules that target the 50S bind between the ribosome’s 
catalytic core, the PTC, and the threshold of the ribosomal exit tunnel.  While many LSU-
targeting classes exist and there are a plethora of outstanding reviews dedicated to a more 
comprehensive list, this section will only focus on a handful demonstrating parent 




Figure 6:  Chloramphenicol Binding.  Top Structure of chloramphenicol.  Middle 
Various binding motifs of chloramphenicol: Green – E. coli (PDB 3OFC), Cyan – T. 
thermophilus (PDB 3OH5), Magenta – D. radiodurans (PDB 1KO1), Yellow – H. 
marismortui (PDB 1NJI).  Bottom Stacking of the p-nitrophenyl can be seen with the 




Steric prevention 1) of tRNA binding; or 2) that either creates a cascade event shifting 
key residues or the tRNA charged end resulting in loss of elongation.   
 Chloramphenicol (Fig. 6) has been shown to have varied binding in a species 
dependent manner.  In both E. coli
49
 and T. thermophilus
50
, it binds distinctly within the 
A-site crevice displacing the charged end of aa-tRNA.  Major binding stability in both 
systems comes about from the p-nitrophenyl moiety being stabilized through a π stack 
with C2452 of the 23S rRNA and the amide seemingly engaged in hydrogen bonding 
with a nonbridging phosphate oxygen of G2505.  Within E. coli, N6 of A2062 appears to 
interact with one of the chlorine atoms.  Interestingly, the primary hydroxyl reaches 
toward a verified potassium ion in T. thermophilus, however it is aligned toward the 
alternate nonbridging phosphate oxygen of G2505 in E. coli.  A secondary binding site 
has been shown both biochemically and crystallographically in archaeal H. marismortui 
further down the tunnel where there is competitive binding with macrolide class 
antibiotics.
51
 This alternate (and exclusive to archaea) binding site results from the loss of 
PTC binding due to a C2055A mutation that drastically disrupts the local orientation and 
the formation of another hydrophobic pocket formed by G2099 and A2100 
(A2058/A2059 in eubacteria).  While the binding of chloramphenicol in D. radiodurans
52
 
shows similarities to that of E. coli and T. thermophilus, it appears to adopt a reversed 
orientation.  This is presumed to be the result of nearby metal ions since regional rRNA 
sequences are conserved.  D. radiodurans crystals show stability afforded by two nearby 
magnesium ions, however they are not observed in T. thermophilus or E. coli systems.  
While evidence suggests the mechanism of inhibition for chloramphenicol to be A-site 
binding interference
53,54




Figure 7:  Clindamycin Binding.  Top Structure of clindamycin.  Bottom Extended 
local contacts by clindamycin in E. coli (PDB 3OFZ).   
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which is reminiscent of macrolide-like inhibition whereby sterics promote premature 
tRNA dropoff.
55-57
  Interestingly, this latter understanding shows less inhibition toward 




Figure 8:  Shared binding sites.  Clindamycin (cyan, PDB 3OFZ); Chloramphenicol 
(yellow, PDB 3OFC); Azithromycin (green, PDB3OI1).  Significant hydrogen 
bonding with A2058 and A2059 for both clindamycin and azithromycin.  
Chloramphenicol and clindamycin share the site with bonding interactions with 
C2452 and G2505.   
 
Lincosamides such as clindamycin (Fig. 7) bind to eubacterial 50S in a similar 
fashion to chloramphenicol inasmuch as they prevent proper positioning of aminoacyl-
tRNA through sterics while overlapping the binding domain of both chloramphenicol as 
well as erythromycin.
52,60
  The major binding stability is found with the galactose moiety 
of lincosamides.  It is here where hydrogen bonding between the three galactose 









substantiated with MLSB-targeting resistance mechanisms.  While these interactions 
provide the stability, the hydrophobic packing of the distal pyrrolidinyl propyl moiety has 
been shown to be responsible for the loss of translation through prevention of peptide 
bond formation.
46,49-52,60,61   
While not clinically viable due to lack of kingdom specificity, puromycin is used 
extensively as a tool in gaining a mechanistic understanding of peptide bond formation.  
Resembling the charged end of a tyrosine-like tRNA including an N6 dimethyl adenine, 
peptide bond formation halts as a result of a nonhydrolyzable amide bond replacing the 
ester linkage.  As a mechanistic probe, puromycin has been used in the fragment assay, a 
tool allowing for understanding PTC activity in the absence of everything save the 50S 
large subunit and a P-site tRNA mimic.
62-64
  However, early iterations of this assay relied 
heavily on high concentrations of alcohol to improve binding affinity of first generation 
P-site substrates.  These nonphysiological conditions were addressed by improvement of 
the substrate through a transition from CCA-fMet to the higher molecular weight CCA-
phenylalanine-caproic acid-biotin (CCA-pcb).
65
  This alteration, along with an extended 
C-puromycin (Fig. 9), was capable of producing the same assay results without the 







Figure 9:  Puromycin structure (Top); Structure of the puromycin analog CCA-pcb 
bound in the PTC of H. marismortui (PDB 1KQS) (Bottom).   
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Streptogramin classes of antibiotics are divided into A and B types that work 
synergistically to inhibit translation (Fig. 10).
66
  While both types are capable of 
independent function as bacteriostatics, the combined effect is profound and 
bactericidal.
67
  A-type streptogramins bind near the entrance of the exit tunnel by 
stacking its conjugated C9-C12 alkenyl stretch with G2061 and the oxazole moiety with 
A2451.  This orientation allows the conjugated amide spanning C4-N7 to displace A2062 
with a 90
o
 rotation from its native position.  B-type streptogramins bind slightly further 
down the exit tunnel from their A counterparts.  The induced rotation of A2062 creates 
both a π-stack interaction with the 3-pyridinol portion of B types as well as two hydrogen 
bonds with the N16 amide and C14 carbonyl.  The importance of this interaction is seen 
with an A2062C mutation that results in a loss of activity for both streptogramins and 
macrolides.  Another crucial stack between the dimethyl aminophenyl moiety and A2058 
is shown as modification of this residue through erm methylation or mutation provides 
streptogramin B resistance.
68,69
  Additional interactions are seen with hydrophobic 
packing of nearby backbone C17-C19 with U2586 as well as the C3 phenyl stacking 
below U2609 ribose.
46





Figure 10:  Streptogramin A/B components Quinupristin and Dalfopristin 
(Synercid) bound to E. coli (PDB 4TP9). A2062 can be seen stacking with the 







Linezolid, an oxazolidinone antibiotic, became clinically available in 2000 with 
much anticipation.  It marked the first truly novel antibiotic design that was not a 
synthetically modified variant of existing scaffolds (Fig. 11).
70
  It showed success against 
existing Gram-positive strains, including vancomycin-resistant enterocci (VRE) as well 
as methicillin-resistant Staphlococcus aureus (MRSA), however does not perform well 
against Gram-negative bacterium due to intrinsic efflux pumps.
71
  There was some 
mystery as to where linezolid bound within the ribosome until initial mutational studies 
in 1999 suggesting it as a PTC binder.
72,73
  Follow up studies continued to support this, 
however use of footprinting with small molecule probes was unable to elucidate the 
region better.  Cross-linking studies finally identified close association with both A2602 
and ribosome-bound tRNA.
74,75
  Crystal structures of linezolid within the 50S of both H. 
marismortui and D. radiodurans solved in 2008 show it as an A-site binder with many 
regional contacts.
76,77
  Interestingly, what was once thought to be a distinctly different 
target based on initial studies and inhibitory profile is staggeringly close, even 
competitively overlapping, the binding sites of many other A-site inhibitors such as 
chloramphenicol and streptogramin A.  More so, the rRNA mutations conferring 
resistance is very extensive, including residues over 15 Å away from the believed active 
binding site.
78
  However, despite this growing body of data and understanding, there is 
still not a consensus as to the full mode of action of this class.  One belief involves the 
ribosomal translation factor, LepA, binding to the PTC in which the oxazolidinone 
compound prevents A-site tRNA from fully accommodating, thus leading to infidelity of 
translation.
79








Figure 11:  Linezolid Binding.  Top Structure of linezolid.  Bottom Two orientations 
of linezolid overlaid. Green: S. aureus (PDB 4WFA), Cyan: D. radiodurans (PDB 
3DLL).   
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As translation progresses, the nascent peptide exits the PTC and the ribosome 
through the exit tunnel that was once thought to provide a passive chute of travel.  Within 
the architecture of the exit tunnel, approximately 10 Å from the PTC, is a natural choke 
point where rProteins L4 and L22 protrude into the tunnel resulting in a halving of the 
diameter.
14,15,17
  Between the PTC and this narrowing exists the macrolide binding site.  
Macrolides, while one of the most diverse and widely used classes clinically, all share a 
similar binding modality and work to stall translation by creating congestion within the 
tunnel.  This is thought to relay back to the PTC and prevent elongation through various 
mechanisms.  Once believed to simply serve as a wall that disallows progression of the 
nascent peptide, it has been shown that peptides ranging from two to ten amino acids long 
accumulate during macrolide-induced translational arrest.  This coupled with the 
understanding that the distance of 10 Å equates to three or four amino acids suggests that 
certain sequences are capable of bypassing the “wall”.
80-91
   
Collectively, this clinically relevant class is generalized as a 14-16 member 
macrolactone ring that is decorated with various sugars.  Erythromycin, the first 
generation macrolide antibiotic dating back to the 1950s, has a desosamine sugar attached 
at C5 as well as a cladinose sugar at C3 (Fig. 12).  One of the most vital interactions 
comes from the 2’ OH on the desosamine forming a hydrogen bond with A2058 of the 
23S rRNA.
49,50,52,93
  The relevance of this binding if further highlighted in recognizing 
that a major macrolide resistance pathway disrupts this interaction through steric 
modification of that critical residue.
60
  Furthermore, corresponding residues in archaeal 
and eukaryotic systems are guanidine, and binding does not occur.
94
  While it has been 
shown that a bacterial system with an A2058G mutation becomes resistant to macrolides,  
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Figure 12:  Structures of representative examples of clinically useful macrolides.   
 
it has similarly been shown yeast carrying a G2058A mutation does not gain sensitivity.
95
  
These last two experiments suggest that, while the presence of A is important, there is 
likely a neighboring influence as well.  Other common interactions involve hydrophobic 
packing of the lactone near A2058 and A2059 along with hydrogen bonding between O4 
of U2609 with the hydroxyl at either C11 or C12.  
In light of growing resistance, newer generations of macrolides were developed through 
semi-synthetic means.  Clarithromycin, differing from erythromycin through C6 hydroxy 
methylation, served as a major advancement by reducing acid sensitivity.  Other 




Figure 13:  Telithromycin Binding.  Top Structure of telithromycin.  Bottom An 
overlay of telithromycin adopting differed positioning of the alkyl-aryl arm bound 
to T. thermophilus (yellow, PDB 3OI3), E. coli (magenta, PDB 3OAT), D. 
radiodurans (green, PDB 1P9X), and H. marismortui (cyan PDB 1YIJ).   
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(azithromycin), or replacement of the C9 ketone with an extended oxime 
(roxithromycin).
96-98
  Clarithromycin was further modified to afford the ketolide subclass 
by hydrolyzing the C3 cladinose sugar followed by oxidation of the alcohol to the 
ketone.
99-101
  Telithromycin, a clinically used ketolide, also has an alkyl-aryl arm 
extending off of a cyclic carbamate spanning C11 and C12 of the macrolactone (Fig. 13).  
This aryl region displays varied binding based on the presence or absence of  
 
 
Figure 14:  An overlay of major LSU-binding drug classes.  Azithromycin (green, 
PDB 3OI1), Synercid (white, PDB 4TP9), Clindamycin (yellow, PDB 3OFZ), 
Linezolid (purple, PDB 4WFA), Chloramphenicol (cyan, PDB 3OFC).   
 
A752:U2609 base pair.  When present as in E. coli or T. thermophilus, this aryl moiety 
projects across the tunnel to engage in a π stack.  However, in the absence of this base 
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pair the extension either projects further down the tunnel as seen in D. radiodurans or 
flips back over itself towards the PTC as in H. marismortui.
49,50,60,102
  
 As shown above, the structural complexity of the various classes is extreme.  In 
overlaying these binding locations, it becomes abundantly clear, however, that there are a 
substantial number of clinically relevant classes that bind within a very narrow window 
(Figs. 8 and 14).  While certain structural elements are mandatory for clinical application, 
portions of the scaffold are capable of synthetic modification.  These regions may be 
modified for improved activity, circumventing resistance mechanisms, or transformation 
from therapeutic to probe.  This last option is desirable for the prospect of being capable 
of enabling analysis of potential interactions between the tunnel and a peptide without a 
reliance mRNA or stalling translation.  This could expand upon the knowledge base of 
situationally gated open reading frames (ORFs) sequestered by leader sequence-
dependent translational stalling. 
1.2.2 Known Exit Tunnel Interacting Peptides 
There exist multiple examples where leader sequences of functional peptides 
serve the purpose of regulating the expression of their downstream partner.  These 
ribosome arrest peptides (RAPs) are able to gate the rate of both transcription and 
translation through varying interactions within the exit tunnel as well as the PTC.
16-18,103
 
As a mechanism of control for intracellular levels of tryptophan, there exist two 
proteins specific to tryptophan whose translation are gated by the leader sequence TnaC.  
The ORF of this leader is regulated by free levels of Trp.  Under high concentrations of 
Trp, TnaC stalling gives way to TnaA (tryptophanase, a protein responsible for metabolic 
degradation of Trp) and TnaB (a Trp-specific permease) having exposed Shine-Delgarno 
sequences.
104-106
  This regulation has been shown to be a result of free L-Trp binding to 
an unknown site near the PTC or narrowly into the exit tunnel.  Initial data suggested the 
binding location to be firmly within the PTC and preventing nascent chain-tRNA 
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hydrolysis, however the interactions between TnaC-I19 and 23S rRNA A2058/9, situated 
well within the exit tunnel, appear to be crucial for Trp-mediated regulation.  When Trp 
levels are low, translation of TnaC completes without issue, hydrolysis of the peptide 
from tRNA occurs, and ribosomal dissociation results.  Upon dissociation, Rho-
termination factors are able to bind and prevent RNA polymerase transcription of 
TnaA/B.  This Rho-dependent termination occurs before functional transcripts are 
polymerized, thus negating the possibility of these Trp-specific housekeeping proteins.
107
 
While various crystallographic, computational, and biochemical techniques have 
shone light on multiple possible interactions, three conserved amino acids within the 24-
mer leader sequence are thought to be responsible for stalling while the previously 
mentioned I19 is strongly implicated in the recognition of free L-Trp.   Interactions 
between TnaC-W12 with K90 and R92 of rProtein L22 are consistently shown to be vital 
to translational arrest.  This interaction dictates the spacing for a feedback relay to the 
PTC and P24.
108
  Cryo-EM data show the neighborhood near P-site tRNA bound P24 of 
A2602 and U2585 repositioned in such a way that would encroach on the binding domain 
of release factor 2.  Between the two exists the third conserved site, D16, which 
seemingly interacts with the 23S A752:U2609 base pair.  As expected, TnaC-mediated 
stalling is abolished when those sites are mutated.
109
  This observation extends to 
ribosomal manipulation, as well, where insertions or mutations to the relevant regions of 
23S and L22 prevent Trp induced stalling. 
Another class of RAPs confers macrolide-induced macrolide resistance through 
polymethylation of A2058, a critical residue of the 23S sequence described above.  
Within the Erm class, there are four distinct leader sequences that are believed to activate 
under two various feedbacks: A2062-initiated cascades (ErmAL1 and ErmAL2/CL) or 
U2585 corruption (ErmBL and ErmDL).
110
   
ErmAL1, the first of two leader sequences for ermA, gates the Shine-Delgarno 
(SD) sequence for ermAL2.  Drug-dependent stalling is required for both leader 
 26 
sequences in order for the translation of ErmA.  ErmAL1 encodes for a 15 amino acid 
protein where stalling has been shown to occur before the nucleophilic attack by E9 on to 
V8.  ErmAL2/CL are highly homologous inasmuch as they are 19 amino acid peptides 
stalling between I9 and N10, again in a drug-dependent manner, thus allowing for the 
ermA/C ORF to become available.  Ala scanning within ermAL1 identified I5, A6, V7, 
and V8 as critical for stalling, while ermAL2/CL requires I6, F7, V8, and I9.
112,113
  
Furthermore, the identities of ermAL1-A6 and ermAL2/CL-F7 appear to have additional 
implications.  These amino acids modulate the reactivity of the A-site tRNA in a manner 
independent of the aminoacyl-tRNA.  This collection of Ala scanning suggests that the 
size of the N-2 position (A6 for ErmAL1 and F7 for ErmAL2/CL) is capable of 
modulating the stalling of these sequences.  If there is a large, bulky side chain, more A-
site inactivation is observed.
111
 
For the above mentioned Erm types, there is seemingly little involvement of the 
N-terminus amino acids preceding the stalling window of four amino acids other than 
their being included in the leader sequences.  Additionally, recognizing that there is 
insufficient distance between the PTC and the site of drug binding (approximately 10 Å)  
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Figure 15:  Possible signal-relay pathways of Erm stalling.  Both relay systems are 
dependent on the cladinose sugar repositioning the nascent Erm peptide.  Figure 
adapted from [16]. 
 
to accommodate a peptide of that length, the long held belief that macrolides stalling 
through simple steric congestion must be reevaluated.  As part of understanding the 
molecular components involved in ErmCL stalling, Vazquez-Laslop et al. performed a 
range of experiments that mutated both rRNA and L22, as well as identified the critical 
moieties of macrolides.
112
  They were able to show that a constriction between the C3 
cladinose sugar and A2062 are vital for stalling (Figure 15).  In the macrolide subclass 
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where the C3 cladinose is replaced with a ketone (ketolides) or under A2062N 
conditions, stalling is not observed.  When a three amino acid deletion is performed on 
L22 within the hairpin protruding into the exit tunnel beyond the drug binding site, a 
substantial reduction in stalling was also observed.  These combined results clearly 
suggest that it is not merely sterics that generate the stalled ribosomal complex.  The 
proposed stalling mechanism, as evidenced by crystallographic and biochemical 
techniques, indicates a relay starting with the peptide sensor, A2062, being knocked out 
of place.  This repositioning ripples through nearest neighbors to perturb A2451/C2453 
within the A-site crevice. 
Other leader sequences within the erm class stall through substantially different 
means.  ErmBL, consistent with the others, is a relatively short leader that stalls between 
P-site bound D10 and A-site A11.
114
  It has been recently shown that the stall occurs 
before nucleophilic attack as A11 does not become incorporated into the peptide product.  
It is believed that this results from drug-dependent locking of an uninduced state.  Peptide 
bond formation is predicated on the proper alignment between the aminoacyl tRNA and 
the P-site ester-linked peptide.  For the A-site CCA conserved tail to appropriately place 
itself for nucleophilic attack, 23S residues U2584 and U2585 must shift out of place into 
an “induced fit” state.  As is the case with previously discussed Erm leaders, ErmBL is 
capable of navigating the restricted aperture of the drug-containing exit tunnel; however 
the resulting deviation off of its native path brings the critical R7 into very close 
proximity with U2586 as well as V9/D10 to U2585.  The resulting downstream effect of 
these newfound interactions is a stabilization of the uninduced state where proper 
positioning and alignment of aminoacyl-K11 is incapable of nucleophilic attack. 
The final Erm leader to be discussed here is ErmDL, and it is by far the most 
unusual within the class.
115
  It has been shown to stall at the necessary “RLR” sequence, 
however, and rather surprisingly, the relative codon placement within a given transcript is 
seemingly irrelevant.  While the wild type peptide is 14 amino acids, this R6-L7-R8 motif 
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was shown to be possible of stalling with truncations of the N-terminus to the point 
where R2-L3-R4 showed near identical levels of drug-dependent stalling.  Moreover, it 
was determined that the stall occurs before the peptide translocates onto R4.  It is 
important to note that this stalling still occurred with R4K mutants, however translation 
returned with R4L variants thereby suggesting the extended cationic side chain plays a 
role.  By use of SHAPE probing followed by corroborating molecular dynamics 
simulations, evidence supports the hypothesis that macrolide binding allosterically 
repositions U2585 within the PTC.  It is believed that this corruption provides suitable 
repositioning of A-site R-tRNA to disallow catalysis. 
The final sequence, known as SecM, is a protein secretion monitor where upon complete 
translation, it is transported to the periplasm followed by rapid protease degradation.  Its 
stalled translation allows for the synthesis of SecA, a translocation ATPase.
116-120
  Of 
those sequences discussed in this review, SecM is by far the longest at 170 amino acids, 
however the all critical interactions occur between the PTC and the L4/L22 choke point 
within the exit tunnel.  Experimentally, the minimum sequence required for ribosomal 
stalling is 150FXXXXWIXXXXGIRAGP166 with stalling occurring prior to 
nucleophilic attack by P166.  In fact, Nakatogawa and Ito were successful in showing that 
the truncated SecM sequence of F150-P166 fused to LacZα is capable of producing 
stalling nearly as efficiently as the full sequence.
116,117
  It has been shown that there are 
two mandatory interactions where modifications to either the nascent chain or the 
ribosomal counterpart lead to full abolishment of stalling.  These take place with 
W155/A751 as well as R163/A2062.  Mutational studies that altered any of these, either 
through identity changes or insertion as is the case with A751, resulted in a full 
transcript.
118,119
  The reported pi stack between W155 and A751 creates a substantial 
compaction of the C-term end of SecM where the relaxed extension is shortened by 
nearly 7 Å, or almost 23%, of the maximum regional length.  This compaction facilitates 
the positioning of R163 where it is believed to force A2062 out of position causing a 
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cascade through A2503 ultimately leading to a 2 Å shift of the P-site tRNA away from A-
site, thus preventing nucleophilic attack and elongation.
120
  Additionally, mutations of the 
β hairpin of L22, namely G91A and A93S, affect interactions with A751 leading to the 
same compromised stalling.  Understandably, the A-site-bound P166 is highly conserved.  
Mutations such as P166A/F/azetidine result in recovery of translation suggesting the local 
changes in the PTC are not solely sufficient in stalling translation.
117
  Instead, use of a 
sterically hindered amino acid with reduced nucleophilicity is also required.  Additional 
sites of significance are F150, G161, and I162 where Ala mutations resulted in partial 




The ribosomal exit tunnel is clearly much more dynamic than was first believed.  This is 
demonstrated by the robust structures of antibiotics that are accommodated and capable 
of specific local interactions.  It is also seen in the capability of various naturally existing 
peptide sequences to modulate the rate of translation in response to various intracellular 
triggers.  However these isolated cases are very specific and a more universal 
understanding of the capabilities within the tunnel is lacking.  This is in part due to an 
inability to deliver an extensive array of probes to parse out a greater scope of the extent 
of interactions.  In an effort to develop methodology to achieve this larger network of 
interactions between the exit tunnel and a nascent peptide, we first recognized that we 
must remove the reliance on a stalled ribosomal complex as they are too specialized and 
limited.
121
  By systematically delivering a diverse set of translation-independent peptides 
of known sequence to shifting but discrete windows within the PTC and exit tunnel, 
probing may be accomplished to observe situational interactions.  To accomplish this, 
LSU-binding antibiotics were covalently modified to accommodate attachment of peptide 
or peptide-like moieties.  Following successful synthesis and characterization, conjugate 
viability was first assessed using a cell-free assay utilizing a luciferase reporter.  Provided 
the conjugates are still showing activity, small molecule probing (footprinting) 
experiments followed to both validate anchor binding location and peptide-exit tunnel 
interactions.  Additionally, whole cell growth inhibition was performed on all derivatives 
to understand potential therapeutic viability of certain modifications.  The modularity of 
this approach offered convergence of full conjugate probes differing at the antibiotic 
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CHAPTER 2  Design and Development of Small Molecule Probes to 
Analyze Ribosome Exit Tunnel-Nascent Peptide Interaction 
2.1  Introduction 
The understanding of how a ribosome functions has grown tremendously over the last six 
decades.  One of the last remaining untold frontiers within the ribosome is the exit tunnel 
and the extent of interactions made within.  Antibiotics highly target a relatively small 
region of the exit tunnel within the large subunit.  In fact, over 25% of the antibiotics 
prescribed in 2011 in the United States of America
1
 were of classes that bind within a 15 
Å window spanning the PTC down to a naturally existing choke point, discussed shortly.  
Throughout this 100 Å long and 20 Å wide tunnel, protein lines a rather small portion 
approximately 20 Å into the tunnel.  The protrusion of ribosomal proteins L4 and L22 
create a choke point, reducing the aperture to a tight 10 Å.  The macrolide class, as well 
as streptogramin B types, exploit this by increasing steric bulk and creating congestion.  
The greater extent of the exit tunnel is lined by ribosomal RNA (rRNA) and with that, a 
strong negative charge from the nonbridging oxygens of the phosphate backbone.  While 
it was once believed that the exit tunnel was more “Teflon”-like in nature, meaning 
allowing a passive route of travel for the nascent peptide, growing evidence is suggesting 
the contrary where situational interactions serve to modulate the rate of translation.  
Partial understanding has been achieved for these situational cases; however a more 
broad understanding of the interactions possible within the exit tunnel has remained 
elusive.  Herein, I will discuss the approach to generate a series of probes capable of 




In addressing how to present our probe peptides, we systematically approached the 
anchor design.  Beginning in the peptidyl transferase center, a puromycin-like anchor was 
first explored.  As stated previously, puromycin is a tRNA mimic that binds very well 
within the PTC, effectively performs the nucleophilic attack and encumbers the nascent 
peptide, however stalls translation after progressing to the P-site due to the 
nonhydrolyzable amide bond replacing the ester bond at the ribose 3’.  With the tyrosine-
like moiety of puromycin selectively projecting to the exit tunnel, we surmised that 
replacement of this moiety with a simple aniloamide group will furnish a puromycin 
mimic which could be easily functionalized with polypetides to arrive puromycin derived 
probes. Toward this end, we synthesized anchor compound 3 starting with puromycin 
aminonucleoside allowing for the incorporation of a synthetically accessible secondary  
 
        
Figure 16:  Synthesis of puromycin-inspired anchor.   
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amine (Fig 16). 
2.2.1 Synthesis of Puromycin-NMIA Coupled Anchor (3) 
To a solution of puromycin aminonucleoside (49.2 mg, 0.167 mmol) in 10 mL 
tetrahydrofuran was added pyridine (0.06 mL, 0.7 mmol).  The reaction was stirred at 
room temperature for 30 min before bringing the temperature to 0 
o
C.  Upon cooling, 
chlorotrimethylsilane (0.13 mL, 1.0 mmol) was added dropwise over 30 min and 
continued to stir for an additional 30 min at 0 
o
C.  After warming to room temperature, 
N-methylisatoic anhydride (38.7 mg, 0.219 mmol) was added and allowed to stir for an 
additional hour.  The reaction was diluted with 10% methanol in ethyl acetate (25 mL) 
and extraction was performed with saturated NH4Cl (3 x 30 mL).  The organic layer was 
first treated with NaSO4 followed by rotary evaporation to afford 64.7mg (90%) of 3 as 
an off-white powder.  
1
H NMR (400 MHz, cdcl3) δ 7.97 (d, J = 7.9 Hz, 3H), 7.42 (t, J = 
7.8 Hz, 3H), 6.68 (d, J = 8.6 Hz, 3H), 6.62 (t, J = 7.5 Hz, 3H), 2.93 (s, 7H), 2.85 (d, J = 
12.7 Hz, 1H), 1.26 (s, 3H); HRMS (MALDI) calc for [C20H25N7O4 + H]
+
 428.2024, 
found 428.2046.  Structural characterization can be found in Appendix A.1.1. 
 Upon challenging compound 3 with the cell-free assay described below in 2.2.2, it 
was shown to have no activity up to a maximum tested dose of 10 µM.  This anchor was 
not pursued further.  We believe that the synthetic modification about the ribose sugar 
clashes with the neighboring region, thus preventing similar binding as seen with the 
inspiring parent. 
2.2.2 Translation Inhibition 
 For all compounds tested within this document, this will be referred to as the 
“cell-free translation inhibition assay”.  This assay functions as an indirect measure of 
translation by determining the concentration of compound required to inhibit 50% of 
ribosomal activity (IC50).  Initial incubation of positive controls or conjugates with 
Escherichia coli (E. coli S30 Extract System for Circular DNA, L1020, Promega) or 
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rabbit reticulocyte (Rabbit Reticulocyte Lysate System, Nuclease Treated, L4960, 
Promega) cellular extracts follow by addition of a plasmid encoding luciferase provides 
varied levels of the final protein as a result of the compound’s ability to inhibit 
translation.  The inclusion of the eukaryotic assay is to ensure that the conjugate probes 
maintain prokaryotic activity.  The prokaryotic assay was used as an initial screen to 
determine whether or not the extensive chemical modification of the parent anchors 
disrupt their ability to target and bind to the ribosome.  If substantial deviation from the 




 The infeasibility of the puromycin analog encouraged the exploration of an 
alternate anchor.  Staying within the PTC, linezolid was seen as a viable possibility.  
With the morpholino and oxazolidinone rings fundamental to binding and the acetamide 
projecting toward the tunnel
2,3
, this latter functionality was selected as the synthetic 
handle. 
2.3.1 Design and Evaluation of Linezolid Classes 
 Starting with a linezolid precursor 4, the primary alcohol was first activated 
through mesylation followed by nucleophilic displacement using sodium azide to afford 
compound 6 in 86% yield (Figure 17).  A portion of 6 was selectively reduced using 
ammonium chloride and zinc powder in ethanol/water under reflux conditions in a 
pressure tube.  Amine 7 was obtained as an off-white powder in 34% yield.   
 
        
 
Figure 17:  Synthesis of linezolid-inspired anchor.   
 
Azide 6 was subjected to copper-mediated cycloaddition with a series of alkyne-
decorated peptides.
4
  The first peptide sequences selected for this “click” reaction were 
highly cationic in nature.  Recalling that the exit tunnel and walls of the PTC itself are 
lined heavily with rRNA, the belief was that greater cationic character would be better 
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suited to engage with the phosphate backbone, thus providing greater opportunity for 
interaction.  The resulting probes 9a and 9b (coupling and deprotection performed by 
Eric Raftery) are seen in Figure 18.  An additional note regarding these probes, they 
contain the identical sequence; however directionality is reversed in 9b from the 
biologically relevant N terminus to C terminus.  It was expected that probe 9a would 
have the ability to bind within the PTC, facilitated by the oxazolidinone anchor, while 
threading the protein portion down the tunnel mimicking a nascent peptide.  Conversely, 
9b would be unable to bind as the exit tunnel would possibly reject the reversed 
sequence. 
        
 
Figure 18:  Linezolid probes.  Cell free translation inhibition assays for the parent 
linezolid as well as the two conjugate probes.  Final “click” and deprotection 
performed by Eric Raftery. 
 
Upon successful synthesis and characterization, probes 9a and 9b were subjected to 
initial assay screening to evaluate probe binding.  Unfortunately, both probes were unable 
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to inhibit translation up to a maximum tested dose of 30 µM suggesting the covalent 
modification was too much to overcome. 
To determine if the sequence and/or length of the appended peptide influence binding, 
another sequence 10, that was substantially shorter, was selected.  Cycloaddition reaction 
between 6 and 10 followed by deprotection afforded probe 11 in high yield (Figure 19).   
        
Figure 19:  Synthesis of Probe 11.   
 
Moreover, to parse out the overall contribution of the triazole, the same sequence was 
coupled via an amide bond in probe 13 (Figure 20).  The synthesis of 13 was 
accomplished in high yield using hydroxybenzotriazole (HOBT) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDCI) promoted coupling reaction 
between amine 7 and peptide 12 followed by TFA deprotection agents. 
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 Subjecting this redesigned series to the same prokaryotic cell-free analysis 
resulted in no translation inhibition for either 11 or 13 up to a maximum tested dose of 25 
µM.  This data continues to reinforce the notion that the linezolid anchor may not be 
tolerant of this level of covalent modification. 
 
        
Figure 20:  Synthesis of Probe 13.   
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2.3.2 Synthesis of Linezolid Class Anchors and Probes 11 and 13 
(R)-3-(3-fluoro-4-morpholinophenyl)-5-(((trimethylsilyl)oxy)methyl)oxazolidin-2-
one (5) 
A solution of (R)-3-(3-fluoro-4-morpholinophenyl)-5-(hydroxymethyl)oxazolidin-2-one 
(3.49 mg, 1.179 mmol) and triethylamine (3.3 mL, 0.024 mmol) in 65 mL 
dichloromethane was held at 0 
o
C and allowed to stir.  To this was added 
methanesulfonyl chloride (1.38 mL, 1.77 mmol) dropwise over 15 min followed by an 
additional 20 min of stirring.  The crude product was filtered and washed with water (3 x 
20 mL) and dried further in a vacuum oven.  The filtrate was moved to a separatory 
funnel and the aqueous layer was washed with dichloromethane ( 3 x 20 mL).  The 
organic fraction was dried with NaSO4 followed by rotary evaporation.  A total of 4.71 g 
(98%) of activated alcohol 5 was combined. 
 
(R)-5-(azidomethyl)-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one (6) 
To a solution of activated alcohol 5 (3.71 g, 9.92 mmol) in 70 mL of dimethylformamide 
was added NaN3 (2.58 g, 40.0 mmol) and was allowed to stir overnight at 75 
o
C.  After 
returning to room temperature, the reaction was diluted by addition of 150 mL water and 
50 mL ethyl acetate.  Extraction was performed with ethyl acetate (3 x 30 mL) and the 
combined organic fractions were dried with NaSO4 followed by rotary evaporation 
resulting in 2.75 g (86%) of azide 6. 
 
(S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one (7) 
To a solution of azide 6 (107.7 mg, 0.335 mmol) in 2 mL ethyl acetate and 0.67 mL water 
was added NH4Cl (45.4 mg, 0.85 mmol) and zinc powder (28.4 mg).  The solution stirred 
under reflux for 6 hrs and allowed to cool.  The solution was filtered over Celite and the 
filtrate was acidified by the addition of 1N HCl (10 mL).  Extraction was performed with 
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dichloromethane (3 x 10 mL).  Confirming removal of azide 6 through TLC (20 DCM: 1 
MeOH: 0.1 NH4OH), the aqueous layer was basified and extracted with dichloromethane 
(3 x 10 mL) to extract out amine 7.  Rotary evaporation of the amine extraction layers 
resulted in 33.6 mg (34%) of amine 7. 
 
Linezolid-QRVVNG triazole conjugate (11) 
To a solution of azide 6 (3.21 mg, 0.010 mmol) and QRVVNGpNH2 protected peptide 
alkyne 11 (14.70 mg, 0.0095 mmol) in 1 mL of tert-butanol and 1 mL of ethanol was 
added tris[(1-benzyl-1H-1,2,3,-triazol-4-yl)methyl]amine (0.63 mg, 0.0012 mmol).  Next 
added was CuSO4·5H20 (0.2 mg, 0.00097 mmol) sonicated in 0.2 mL H2O followed by 
sodium ascorbate (0.8 mg, 0.004 mmol) sonicated in 0.2 mL H2O.  The reaction stirred 
overnight at 45 
o
C.  The reaction was allowed to cool, diluted by addition of 50 mL ethyl 
acetate and transferred to a separatory funnel.  Extraction was performed with a 4 NH4Cl 
: 1 NH4OH solution (2 x 10 mL).  The organic layer was dried with NaSO4.  Solvent was 
removed by rotary evaporation.  The white solid obtained above was dissolved in 
TFA/TIPS/phenol (90:5:5, 2 mL) and stirred at room temperature for 2 h. Rotary 
evaporation followed by addition of diethyl ether (1 mL) lead to a white precipitate. The 
solution was vortexed for 1 min before pelleting through centrifugation (13,200 rpm, 5 
min) followed by removal of the supernatant. The final pellet was dissolved in 
acetonitrile (0.75 mL) and deionized water (0.25 mL) was added, and the mixture was 
shaken. The final aqueous layer was flash frozen in dry ice/acetone and lyophilized 
overnight to give 11 as fluffy, white solid (6.96 mg, 71%).  
1
H NMR (400 MHz, d2o) δ 
7.86 (s, 1H), 7.05 (dd, J = 44.2, 33.6 Hz, 1H), 4.36 (s, 1H), 4.28 (s, 1H), 4.02 (s, 1H), 
4.00 (s, 1H), 3.92 (s, 1H), 3.79 (s, 1H), 3.08 (s, 2H), 2.98 (s, 1H), 2.75 (s, 1H), 2.72 (s, 
1H), 2.62 (d, J = 2.6 Hz, 3H), 2.30 (s, 3H), 2.02 (s, 2H), 1.92 (s, 2H), 1.67 (s, 2H), 1.48 




 515.7701, found 515.7707.  Structural characterization can be found in Appendix 
A.1.1. 
Linezolid-QRVVNG amide conjugate (13) 
A solution of QRVVNG protected carboxylic acid peptide 12 (14.8 mg, 0.0098 mmol) in 
3 mL of dichloromethane was cooled to 0 
o
C.  To this was added hydroxybenotriazole 
(1.9 mg, 0.014 mmol) and this was allowed to stir for 5 min.  Next was added 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (2.3 mg, 0.012 mmol) followed by another 10 min 
stirring at 0 
o
C.  Finally, a solution of amine 7 (6.9 mg, 0.023 mmol) in Hunig’s base 
(0.0069 mL) and 2 mL dichloromethane was added to the peptide solution.  This was 
allowed to warm to room temperature and react overnight. The reaction was stopped by 
quenching with water and transferred to a separatory funnel.  Dichloromethane (20 mL) 
was added and the organic layer was extracted with alternate washings of saturated 
NaHCO3 and water (2 x 20 mL).  The organic layer was dried with NaSO4.  Solvent was 
removed by rotary evaporation.  The white solid obtained above was dissolved in 
TFA/TIPS/phenol (90:5:5, 2 mL) and stirred at room temperature for 2 h. Rotary 
evaporation followed by addition of diethyl ether (1 mL) lead to a white precipitate. The 
solution was vortexed for 1 min before pelleting through centrifugation (13,200 rpm, 5 
min) followed by removal of the supernatant. The final pellet was dissolved in 
acetonitrile (0.75 mL) and deionized water (0.25 mL) was added, and the mixture was 
shaken. The final aqueous layer was flash frozen in dry ice/acetone and lyophilized 
overnight to give 13 as fluffy, white solid (8.00 mg, 86%). 
1
H NMR (400 MHz, d2o) δ 
7.27 (d, J = 13.2 Hz, 1H), 7.03 (s, 1H), 4.36 (s, 1H), 4.19 (s, 1H), 3.99 (s, 1H), 3.94 – 
3.84 (m, 2H), 3.71 (d, J = 12.2 Hz, 5H), 3.50 (s, 2H), 2.95 (d, J = 28.0 Hz, 5H), 2.49 (s, 
2H), 2.21 (s, 2H), 1.91 (s, 4H), 1.58 (s, 2H), 1.48 – 1.28 (m, 2H), 0.81 – 0.58 (m, 12H); 
HRMS (ESI) calc for [C41H65FN14O11 + H]
+
 949.5009, found 949.5014.  Structural 
characterization can be found in Appendix A.1.1. 
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2.4 Telithromycin 
This work was published with multiple contributors.  Their contributions will be pointed 
out when appropriate.   
 
Washington, A. Z., Benicewicz, D. B., Canzoneri, J. C., Fagan, C. E., Mwakwari, S. C., 
Maehigashi, T., Dunham, C. M. and Oyelere, A. K. (2014) Macrolide-peptide conjugates 
as probes of the path of travel of the nascent peptides through the ribosome. ACS Chem 
Biol 9, 2621-2631 
 
As discussed in 1.2.1, telithromycin displays species-dependent orientation of its alkyl-
aryl arm in response to the presence or absence to the Watson-Crick interaction of 
U2609-A752 of the 23S rRNA.  In each of the structures, the alkyl-aryl arm is engaged in 
different stabilizing interactions (Figure 21). In E. coli and T. thermophilus, the arm is 
stabilized by stacking against the rRNA A752:U2609 base pair. In H. marismortui, which 
lacks the A752:U2609 base pair, the arm is stabilized by a hydrogen bond with the O2’ of 
U2609 while in D. radiodurans, the arm extends down the exit tunnel and is potentially 
engaged in van der Waals interactions with the rRNA.
6
 This dynamic flexibility of the 
alkyl-aryl portion can be exploited as a means of potentially doubling the intended 
probing window.  By using the same peptide sequences as those in 9a and 9b, the 
reversed sequence could conceivably self-align and project back toward the PTC, thus 
providing a platform to probe in both directions.   
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Figure 21:  Telithromycin.  Structure of Telithromycin (left).  Path of alkyl-aryl arm 
changes based on response to U2609-A752 base pair of the 23S rRNA (right).  
Yellow: T. thermophilus (PDB 3OI3)
8
; Green: D. radiodurans (PDB 1P9X)
9
; Cyan: 
H. marismortui (PDB 1YIJ)
10
; Magenta: E. coli (PDB 3OAT)
11
.  All images 




2.4.1 Design and Probe Synthesis 
We designed a series of telithromycin-derived peptide-ketolide (or peptolide) probes 
which have the phenyl and the imidazolyl groups substituted by peptides and 1,2,3-
triazole ring, respectively. The synthesis of these peptodies was accomplished through 
the Cu(I) promoted cycloaddition reaction of azido-ketolide intermediates and 
appropriately protected terminal alkyne modified peptides (full synthesis performed by 
Derek Benicewicz).
12,13
 Of these azido-ketolides, there is variation about the alkyl region 
spanning the carbamate and the azide: a butyl group used to most closely mimic the 
parent telithromycin, and a propyl variant to offer a slightly shifted probing window.  The 
peptide portions differ in the (1) direction of attachment (amino or carboxy terminus), (2) 




the peptide moiety. These variations are incorporated into the design in order to 
investigate the influence of both the nature of individual amino acids, and the orientation 
of the peptide chain within the exit tunnel on the affinity of the peptolides for the 
ribosome.  The combination of the four peptide probes and two linker lengths resulted in 
a series of eight total probes as shown in Figure 22. 
        
Figure 22:  Peptolide final structures.   
 
 The NLS and rNLS are the same reversed pair used within the linezolid series 
where they are highly cationic carrying a +5 charge at physiological pH.  The second 
level of modification is that the rNLS sequence is reversed such that the attachment to the 
ketolide base is near the N terminus.  This sequence reversal as well as the flexibility of 
the alkyl-aryl arm of telithromycin discussed above is intended to provide the opportunity 
for the peptide to self-align to adopt the correct N term  C term projection by flipping 
over the macrolactone ring and projecting the C terminus back to the PTC.   
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 The other sequences were designed primarily to evaluate the charge effect where 
the highly aromatic plicatamide (PLI) sequence holds a +3 charge and the Arg-Gly-Asp 
tetramer repeat (RGD) is Zwitterionic neutral overall while at physiological pH.  
2.4.2  Peptolide Cell-Free Assay Evaluation 
 Similar to previous series’, the cell-free luciferase reporter assay was employed to 
validate the probes’ ability to maintain translation inhibition activity.  Additionally, by 
independently measuring the effects of the deprotected, uncoupled peptides on luciferase 
activity, we were able to evaluate the effect of the coupled probe as well as the potential 
contribution of the peptide alone on translation inhibition. 
 It was observed that all coupled peptolides not only retained potent translation 
inhibition capability, but the best performer of the series, 14b, performed on par with 
both macrolide positive controls.  This inhibition was shown to be exclusive to the full 
probe and not an inherent effect of the peptide portion alone as displayed by no inhibition 
activity up to the maximum tested dose of either 250 or 1000 µM.   
 A remarkable difference in the inhibition profile can be seen when put in context 
of both the linker length as well as the overall charge of the peptide portion.  Collectively, 
the butyl linker performed better.  This is not unexpected as the C4 linker is the nearest 
mimic to telithromycin.  In looking at the effect of the amino acid composition, and thus 
the overall charge, there is a strong correlation between the higher cationic character of 
the probe and the increased inhibition.  This observation suggests that the positively 
charged peptides such as 15 and 16 have an enhanced affinity for the phosphate backbone 
of the rRNA which lines the exit tunnel. Since the peptide tails alone did not cause 
significant translation inhibition, it is believed that the ketolide macrocyclic ring of the 
peptolide acts as an anchor whose affinity for the ribosome is in turn modulated by the 
extent of accommodation of the peptide moieties within the ribosome.  The impact of 
directionality of the peptide could not be determined from this assay.  When comparing 
 64 
the matched pairs of 14a/14c and 14b/14d there is virtually no deviation in the inhibition 
values.  However, based on these data alone, it cannot be determined whether the 
peptides are adopting reversed directions. 
 In expanding the analysis to those probes with a +3 overall charge (14e/f) and the 
zwitterions (14g/h), the charge clearly dominates the major influencing factor.  Reducing 
charge by two results in a 3- to 4-fold reduction in inhibition activity.  Amazingly, those 
of the zwitterion class are not just the worst within the series, but the propyl linker 
zwitterion 14g displays nearly a 50-fold reduction in inhibition activity over 14a. 
The peptolides were evaluated in a eukaryotic translation system to assess their 
selectivity for prokaryotic ribosomes over eukaryotic ribosomes. As anticipated, the 
control TE-802 and clarithromycin are inactive at 250 M. The majority of the peptolides 
and the analogous deprotected peptides were unable to inhibit eukaryotic translation at 
the same maximum tested dose. However, the unattached deprotected peptide 17 showed 
slight translation inhibition with an IC50 of 205µM, resulting in only a ~ 4-fold selectivity 
over the prokaryotic ribosome. When coupled to the butyl linked ketolide, the resulting 
peptolide 14f showed significant inhibition of eukaryotic translation with an IC50 of 
38µM. This suggests there are subtle architectural differences between the eukaryotic and 
prokaryote exit tunnels which allow for more favorable interactions with peptide 17 and 
its analogous peptolide 14f within the context of the eukaryotic ribosome. 
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Table 1:  IC50 cell free assays translation inhibition activity of peptolides against 
prokaryotic and eukaryotic ribosomal preparations. Luciferase activity was used as 
a reporter of translation inhibition in both systems. IC50 values were obtained from 
an average of three independent experiments. * No inhibition at maximum tested 
concentration (250 µM).  ** Maximum tested concentration increased 4-fold to 
obtain information about the extent of selectivity over RRL.  # Values determined 





















E. coli Rabbit Retic. 
Compounds IC50 (µM) IC50 (µM) 
#
 
14a 1.32 ± 0.08 > 250 
14b 0.67 ± 0.28 > 250 
15 > 250*
#
 > 250 
14c 1.86 ± 0.35 > 250 
14d 1.10 ± 0.22 > 250 
16 > 250*
#
 > 250 
14e 4.32 ± 0.25 140 




14g 56.00 ± 9.60 > 250 
14h 7.41 ± 1.20 > 250 
18 > 250*
#
 > 250 
TE-802 0.52 ± 0.05 > 250 
Clarithromycin 1 0.32 ± 0.12 > 250 
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2.4.3 Chemical Footprinting of E. coli 23S rRNA 
 Chemical footprinting of the E. coli 23S rRNA was performed with dimethyl 
sulfate (DMS) and 1-cyclohexyl-(2-morpholinoethyl)carbodiimide metho-p-
toluenesulfonate (CMCT) according to the following protocol: 
2.4.3.1 Probe binding 
 All probes and the synthetic precursor were incubated at a final concentration of 
150 µM with 100 pmol E. coli 70S ribosomes (New England Biolabs), whereas 
clarithromycin was incubated at a concentration of 50 µM. Binding was performed in 
binding buffer (10 mM HEPES, 10 mM MgCl2, 60mM NH4Cl) at 37°C for 30 min. 
2.4.3.2 DMS Chemical Modification 
 DMS chemical modification was performed on intact 70S E. coli ribosomes in the 
absence and presence of bound drug. Approximately 50 µg of intact ribosome, or 
ribosome-probe complex, in 25 µM DMS buffer (80 mM K-HEPES, 10 mM MgCl2, 100 
mM NH4Cl) was aliquoted and to this was added 1 µL DMS Stock (880 mM DMS in 
abs. EtOH) and the mixture was then incubated for 10 min at 37°C. The reaction was 
terminated by the addition of 12.5 µL of DMS stop buffer (1 M Tris-HCl, 0.1 M EDTA, 
1 M β-mercaptoethanol, pH7.5). Ethanol precipitation was followed by RNA extraction. 
The RNA pellet was resuspended in 400 μL extraction buffer (0.3 M NaOAc (pH 6.5), 
0.5% SDS, 5 mM EDTA (pH 8.0)) at room temperature.  This was subsequently 
extracted three times via addition of 400 μL of acid phenol chloroform (pH 4.5, 
Invitrogen).  The final RNA fraction was ethanol precipitated and the pellet was 
resuspended in H2O (final concentration: 0.4 μM).  Aliquots were stored at -80
o
C. 
2.4.3.3 CMCT Chemical Modification 
 CMCT chemical modification was performed on intact 70S E. coli ribosomes in 
the absence and presence of bound drug. Approximately 50 µg of intact ribosome, or 
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ribosome-probe complex, in 25 µM CMCT buffer (50 mM potassium borate pH 8.0, 10 
mM MgCl2, 100 mM NH4Cl) was aliquoted and to this was added 12.5 µL CMCT Stock 
(100 mM CMCT in CMCT buffer) and the mixture was then incubated for 10 min at 
37°C. The reaction was terminated by the addition of 2.5 volumes of -20°C 95% EtOH. 
Subsequent ethanol precipitation was followed by RNA extraction as described above. 
2.4.3.4 Reverse Transcription 
 A list of primer sequences was generously provided by Dr. Alexander Mankin. 
DNA primers were purchased from Keck Biotechnology (New Haven, CT).  An array of 
primers was initially purchased with the intent of covering as much of the 23S rRNA 
strand as possible. After footprinting analysis of all primers, the primer yielding the most 
useful data, named primer 2180, has the following sequence: 5`-
GGGTGGTATTTCAAGGTCGG-3`. Primer 2180 is named as such because the 5` G of 
the primer anneals to position 2180 (E. coli numbering) of the 23S rRNA. Primer 
concentration was determined by UV-vis spectroscopy in 1 cm path length quartz 
cuvettes using molar extinction coefficients determined by OligoAnalyzer (IDT).  
A working primer stock (2.0 μM) in H2O was made fresh for each reaction.  A 
hybridization buffer (225 mM K-Hepes (pH 7.0), 450 mM KCl) was used to bring primer 
concentration to 1.0 μM.  This primer mix (2 μL) was added to tubes containing RNA 
(0.8 μmol).  Annealing proceeded by placing tubes in a water bath at 90
o
C for 1 min, and 
allowed to cool to room temperature.  While cooling, a master mix was prepared using 20 
μL 5x First Strand Buffer (supplied with RT enzyme, Invitrogen), 150 μCi dATPα
35
S 
(PerkinElmer), 6.6 μL dNTP mix (110 μL 1mM d(T, G, C)TP, 6 μL 1 mM dATP, 664 μL 
H2O), and 1 μL each of RNasin Plus (Promega) and 100 mM dithiothreitol (DTT). 
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 Upon completion of annealing, samples were briefly centrifuged at room 
temperature.  Each tube received 2 μL master mix and the sequencing tubes received the 
appropriate ddNTP (1 μL, 9 μM).  Added last to each tube was 200U SuperScript II 
reverse transcripase (Invitrogen).  Tubes were gently mixed and centrifuged before being 
placed in a heating block at 55
o
C for 30 min.  Chase was initiated by addition of 1 μL 
dNTP (100 mM) to each tube and 1 μL appropriate ddNTP (402 mM) to sequencing 
tubes.  Tubes were placed back in the heating block at 55
o
C for 15 min.  The reaction was 
terminated by the addition of precipitation buffer (75 μL, 95% ethanol, 0.3 M NaOAc pH 
6.5, 4
o
C) and centrifuged for 90 min (13,200 rpm, 4
o
C).  The supernatant was removed 
and the pellets were dried and resuspended in 10 μL loading buffer (95% formamide, 10 
mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue, pH 11). 
2.4.3.5 Analysis of Footprinting by Gel Electrophoresis 
 Samples were analyzed by running on a 5% polyacrylamide gel in a Sequi-Gen 
GT system (Bio Rad).  The gel and 1x TBE buffer (100 mM Tris, 90 mM boric acid, and 
1 mM EDTA) were brought to temperature by pre-running at 55 W to 50
o
C.  Lanes were 
thoroughly flushed with buffer and loaded with 1 μL of sample each.  Migration occurred 
from 45 to 90 min at 55W and 50°C.  Gels were transferred to Whatman paper and were 
fixed in 20% EtOH for 20 min.  They were then dried under vacuum for 90 min at 80
o
C.  
Once dry, gels were exposed onto a phosphor screen (GE Healthcare) overnight.  Screens 
were scanned on a Typhoon Trio+ (GE Healthcare) and digital images were analyzed 
with Multi Gauge (FujiFilm). 
2.4.4 Peptolide Cell-Free Assay Evaluation 
The above translation inhibition data does not suggest that the mode of inhibition 
is the same as the unadorned ketolide parent.  To elucidate the binding location, small 
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molecule probing was utilized.  This probing was performed on the E. coli 23S rRNA of 
intact 70S. Dimethylsulfate (DMS) and N-cyclohexyl-N′-(2-
morpholinoethyl)carbodiimide (CMCT) were employed as the nucleic acid modifying 
agents.
14,15
  DMS footprinting gel in Figure 23 shows a clear peptolide footprint at the 
residue A2058 of the E. coli 23S rRNA. In lanes 5 and 6 are unmodified and DMS-
modified rRNAs respectively in the absence of probes. Any differences between these 
lanes highlight residues that are available for DMS modification, ie solvent exposed 
adenines. Similarly, any differences between lane 6 and lanes 7-16, lanes containing 
rRNAs that are DMS-modified after drug or probe binding, will highlight sites of probe-
dependent interactions either through protection or enhancement of alkylation by DMS.  
The reduction in intensity seen at nucleotide A2058 in the presence of each peptolide is 
clear evidence of a drug binding footprint. This is an expected site of drug interaction as 
A2058 is known to interact with the macrolide ring upon binding to the well-defined 
macrolide binding pocket of the ribosome.
16-19
 This footprint confirms that the binding 
target of the macrocycle moieties of the peptolide probes is indeed the same as the parent 
ketolide drug.  
For nearly all peptolides, the A2058 band is barely visible except for 14g, the 
peptolide derived from the propyl-linked ketolide and the zwitterionic peptide 18, which 
has a relatively more pronounced A2058 band (lane 15). The reduction seen in peptolide-
induced protection from DMS modification at nucleotide A2058 by peptolide 14g, in 
comparison to the other peptolides, suggests a decreased binding affinity of peptolide 14g  
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Figure 23:  DMS small molecule probing (A2058).  DMS footprinting of the whole 
70S E. coli ribosome.  Primer regions contained within the 23S rRNA. Dideoxy 
sequencing lanes G, C, A and T (lanes 1-4) followed by unmodified rRNA (lane 5), 
DMS modified 23S rRNA (lane 6), DMS modified 23S rRNA in presence of 
clarithromycin and butyl azido ketolide intermediate (lanes 7-8, respectively), 23S 
rRNA DMS modified in the presence of 14a-h (lanes 9-16, respectively). (Work 
performed by Dr. Joshua Canzoneri) 
 
in the macrolide binding pocket. This decreased binding affinity corroborates the E. coli 
translation inhibition study which showed peptolide 14g has the weakest translation 
inhibition activity (IC50 value of 60 µM, Table 1). DMS probing of the other key residues 
within the large subunit did not reveal strong peptolide-induced protection (data not 
shown). Importantly, A752 is protected by TEL presumably due to the placement of the 
alkyl-aryl arm into this section of the tunnel.
20
  However, A752 is not protected by any of 
the peptolides (Figure 24) indicating that the peptide moiety of the peptolides is not 
oriented toward the A752:U2609 base pair and projecting further down the exit tunnel.  
In light of this A752 data, we probed the PTC side of the exit tunnel scanning for 
additional interactions.  In doing so, we observed a peptolide-dependent protection at 
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U1963 using CMCT.  In looking at lanes 6-8 (Figure 25), there is no change in the 
amount of CMCT modification in  
      
Figure 24:  DMS small molecule probing (A752).  DMS footprinting of the whole 
70S E. coli ribosome.  Primer regions contained within the 23S rRNA.  Dideoxy 
sequencing lanes G,C,A and T (lanes 1-4) followed by unmodified rRNA (lane 5), 
DMS modified 23S rRNA (lane 6), DMS modified 23S rRNA in presence of 
clarithromycin and butyl azido ketolide intermediate (lanes 7-8, respectively), 23S 
rRNA DMS modified in the presence of 14a-h (lanes 9-16, respectively). 
 
the presence or absence of macrolide binding.  This tells us that the selective protection 
observed in lanes 9-16 are a result of the peptide portion.  U1963 is part of Helix 71 
(H71) located within domain IV of the 23S which forms part of the front rim of the 
peptidyl transferase active site cleft.
4
 The CMCT protection seen here suggests that these 
peptolides all adopt a similar binding orientation such that their peptide moieties mimic 
the path a nascent peptide would travel extending from the PTC to the proximity of the 
entrance to the exit tunnel.  Ribosomal rRNA U1963 is a crucial residue within the 
overlapping binding sites of RRF, EF-G, and the P-site tRNA
23
 suggesting a plausible 
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mechanism of translation inhibition by inhibiting the binding of these critical translation 
components.  Both the N- and C-linked peptolides 14a-d cause indistinguishable    
   
 
Figure 25:  CMCT small molecule probing (U1963).   CMCT footprinting of the 
whole 70S E. coli ribosome.  Primer regions contained within the 23S rRNA. 
Dideoxy sequencing lanes G,C,A and T (lanes 1-4) followed by unmodified rRNA 
(lane 5), CMCT modified 23S rRNA (lane 6), CMCT modified 23S rRNA in 
presence of clarithromycin and butyl azido ketolide intermediate (lanes 7 and 8, 
respectively), 23S rRNA CMCT modified in the presence of 14a-h (lanes 9-16, 
respectively). 
 
protection of U1963, indicating the tolerance of the exit tunnel for either the biological N 
→ C or the abiological C → N orientation of nascent peptide.  
2.4.5 Biochemical Validation Through Crystallography 
 In collaboration with Professor Christine Dunham of Emory University, we were 
able to crystalize peptolide 14c, the propyl linker ketolide coupled with the reversed NLS 
sequence, to 3.6 Å.  The 70S-peptolide 14c structure shows the ketolide macrocyclic ring 
adopts a similar orientation within the 50S subunit as observed in previous structures.
16-18
 
Specifically, the desosamine sugar of the ketolide hydrogen bonds with the 23S rRNA 
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A2058 and the surface of this ring forms hydrophobic packing interactions with the bases 
of U2611, A2058, and A2059. These results show that the addition of the peptide tail 
does not alter the binding profile of our ketolide anchor when compared to that within 
other crystal structures. 
 
 
Figure 26:  Crystal Structure of peptolide 14c.  Crystallographic evidence of 
peptolide binding and orientation.  Hydrogen bonds highlighted by distance 
measurements.  The disordered region is shown by the box filled with the missing 
residues.  Lys9 is shown as Ala due to disorder.  Crystal structure solved by Dr. 
Christine Dunham (Emory University). 
 
 Continuing the investigation of the more complete binding profile, it was 
observed that the alkyl linker continues to travel down the tunnel, adopting an orientation 
akin to that observed of the alkyl aryl arm of telithromycin in D. radiodurans.  However, 
the peptide portion seems to reverse direction and project back over the macrolactone 
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ring, potentially as a means of reorienting to the proper C term  N term alignment.  
This realignment is believed to be stabilized by two hydrogen bonds.  The peptolide Lys6 
hydrogen bonds to a phosphate oxygen of 23S rRNA C2442 while Lys7 hydrogen bonds 
with the side chain of His69 of ribosomal protein L4 (Figure 26).  The peptide tail 
continues to adopt this orientation as it traverses the path back to the PTC, however the 
electron density of the peptolide tail is disordered beyond the seventh amino acid 
resulting in an inability to build the remainder of the tail. 
 Despite the region associated with the tail being disordered, there is still clarity 
about the 23S residues.  As a result, an overlay of multiple T. thermophilus 50S 
ribosomal subunits provided an opportunity to see drug- or probe-dependent shifts within 
the region.  PDB 3UXR was used as a “naked” ribosome to provide a natural state of 23S 
residues, PDB 3OI3 was used to view residue states as a result of telithromycin binding, 
and PDB 4W2B was used to view residue states with 14c bound.  We first analyzed any 
potential deviation in U1963 that may account for the footprint observed.  The protection 
shown biochemically must have been the result of downstream effects since the distance 
was too far to be due to direct peptolide protection.  By overlaying the three ribosomal 
structures and isolating residues of interest, we are afforded the opportunity to visualize 
the rationale for the biochemical data.  In looking at U1963, we are able to see that the 
positioning within the naked or telithromycin-containing ribosomes is highly similar.  
More so, it is understandable why they show such a strong footprint seeing as how it is 
extremely solvent exposed.  However, in the presence of our 14c probe, we see that 
U1963 is clearly shifting out of its natural position (Figure 27).  Toward exploring the 
cause for this structural change, we scanned the local region and identified a likely 
Watson-Crick interaction formed between U1963 and A1936 at a distance of 3.1 Å.  The 
overlay of A1936 from all three PDBs does not show a significant shift when compared 
to the natural state (cyan, Figure 27) however we could find no deviation within the 
phosphate backbone surrounding either residue.  With crystallographic data supporting 
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our footprinting, it is clear that a downstream effect is responsible for this migration of 
U1963 that allows it to adopt a favorable Watson-Crick interaction.  Once engaged in 
this, CMCT modification would become disallowed.  This shifting of U1963 and 
resulting Watson-Crick interaction is clearly visible in Figures 27 and 28.  
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Figure 27:  U1963 movement.  Space fill model showing region around U1963.  Blue: 
PDB 3UXR
32
, representing the natural state when no macrolide is bound.  Green: 
3OI3
7
, representing the shifting of nucleotides as an effect of telithromycin binding.  
Magenta: 4W2B
5
, representing the shifting of nucleotides in the presence of probe 




      
Figure 28:  U1963 Adopted Base Pair.  Coloring is the same as in Figure 26.  New 
base pair between U1963 and A1936 can be seen at a distance of 3.1 Å.  No major 
movement shown in A1936, however U1963 realigns upon 14c binding to sequester 




2.4.6 Further Analyses of Peptolide-Induced Conformational Changes within the 
Exit Tunnel 
 Encouraged by this overlay, we sought out other possible sites of interaction 
supported by crystallography but perhaps unobserved by footprinting.  By starting at 
residues closest to the peptolide 14c and moving outward, we identified three additional 
sites of shifted bases.  The first, C790, becomes displaced upon probe binding (Figure 
29).  Expanding past this, we observed an additional interaction at U2506 where the 
residue seemingly projects inward toward the probe (Figure 30).  This suggests an 
additional hydrogen bond previously not identified.  Lastly, we observed a deviation of 
U2585 pitching inward, again toward the probe (Figure 31).  These last two interactions 
involving U2506 and U2585 are very interesting as the portion of the probe responsible 
for the interaction is held within the disordered region.  Collectively, these data show an 
extensive network of interactions spanning the region of the PTC to the macrolide 
binding site. 
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Figure 29:  C790 Migration.  Coloring is the same as in Figure 26.  C790 clearly is 
forced out of position through a steric interaction as a result of 14c probe binding. 
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Figure 30:  U2506 Migration.  Coloring is the same as in Figure 26.  U2506 is 




     
 
Figure 31:  U2585 Migration.  Coloring is the same as in Figure 26.  U2506 is 





 By progressing systematically through potential anchors starting with the PTC 
and moving down the exit tunnel, we have successfully developed a set of probes, proven 
not only to be a potent inhibitor of translation, but more importantly, capable of 
delivering a broad range of peptide sequences to a known location within the exit tunnel.  
These sequences were shown to not be travelling continually down the tunnel, but were 
in fact reversing orientation and aligning to the PTC regardless of the directionality 
engineered within the design.  Further evidence of this reversed orientation was shown 
with additional footprinting data showing a probe dependent protection at U1963, a 
residue shown to be engaged in a new Watson-Crick interaction with A1936.  X-ray 
crystallography corroborated these data. Crystal structure of 14c bound to the 70S 
bacterial ribosome revealed that the macrolide ring of the peptolide binds in the same 
position as other macrolides while the peptide tail adopted an orientation which is an 
exact mimic of the orientation of the nascent peptide during elongation.  Further analyses 
of this crystal structure revealed an extensive network of 23S nucleotides shifting out of 
normal alignment in response to the probe.  These exit tunnel nucleotide conformation 
changes were still visible despite density mapping for the probe itself becoming too 
disordered to predict.  This study marks the first time that a molecular probe of this 
nature not only was shown to bind successfully through rRNA footprinting as well as 
crystallography, but also establish a series of probe-dependent interactions within a 
discrete window of the exit tunnel.  Improvements upon this design will focus on the 
probe’s ability to project further down the exit tunnel to complement the probes which 
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CHAPTER 3  Design Approach Toward Peptolide Probes with 
Affinity for the L4/L22 Constriction Section to the Egress Point at 
the Back of the 50S Subunit  
This work was published under the following reference: 
Washington, A. Z., Tapadar, S., George, A. and Oyelere, A. K. (2015) Exploiting 
translational stalling peptides in an effort to extend azithromycin interactions within the 
prokaryotic ribosome nascent peptide exit tunnel.  Bioorg Med Chem 23, 5198-5209. 
Portions of the manuscript are presented here without modification. 
 
3.1 Introduction 
 Efforts aimed at elucidating the nascent peptide-tunnel interaction have been 
hampered by a dearth of molecular probes. As discussed in Chapter 2, a class of 
oligopeptide telithromycin-like (peptolides) probes were capable of furnishing atomic 
level information about specific interactions between the ribosomal exit tunnel and 
models of nascent peptides.
1
 However, these were all shown to interact between the 
peptidyl transferase center and the L4/L22 constriction section regardless of the inherent 
directionality incorporated into the peptide sequence.  Both probes mimicking the 
biologically N term  C term and the reversed C term  N term, intended to self-align 
by reversing direction, were biochemically demonstrated to adopt an orientation pointing 
exclusively toward the PTC.  Earlier studies with translation stalling peptide sequences, 
including SecM, ErmBL and TnaC, have provided evidence of direct interaction of the 
nascent peptide with the components of the exit tunnel.
2-4
  Toward an alternative 
structure-guided optimization of macrolides, the X-ray structures of azithromycin bound 
to the ribosomes from various prokaryotes was analyzed
5,6




Figure 32:  SecM Design. PBD 3OI1
5 
showing the overlay of ribosome-bound 
azithromycin and modeled SecM.  Top Cross section of the exit tunnel.  50S shown 
in grey, SecM model in white, azithromycin in yellow.  PTC is at the top of the 
image.  Bottom View atop the exit tunnel where W155 and A751 are shown with 3.5 
Å separation. Images generated using PyMOL.
9




structure of SecM bound to E.coli ribosome.
2
 As discussed in Chapter 1.2.2 of this thesis, 




, and mutational studies have shown that W155A led to 
the abolishment of translational stalling.
7,8
  Simulations performed by Gumbart et al.
2
 
suggested that the stacking of W155 with A751 of the 23S rRNA is vital to stalling.
2,7,8
  
Our analyses of the X-ray structures of azithromycin bound to the ribosomes and the 
simulated structure of SecM 
 
suggested that the crucial SecM W155 residue could be 
incorporated into the azithromycin endocyclic amine (N-10, adopting the azithromycin 
ring numbering by Hansen et al)
5
, possibly resulting in N-10 functionalized azithromycin 
analogs with enhanced affinity for the prokaryotic 50S ribosomal subunit. This rational 
designed was informed by an overlay of both SecM simulations and azithromycin crystal 
structures (Figure 32) showing the peptide backbone virtually passes right through the N-
10 of azithromycin. 
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3.2 Azith-Trp Conjugate Design and Synthesis 
 To confirm this deduction, we designed a series of azithromycin analogs modified 
at the N-10 with indoles. These compounds were designed such that their indole moiety 
will mimic the 23S A751/SecM W155 stacking. Beginning with commercially available 
azathromycin, we synthesized two distinct alkynl azithromycin intermediates (synthesis 
performed by Dr. Subhasish Tapadar).  We chose these two distinct moieties – alkyl and 
alkyl aryl – as linkers to connect the indole analogs to the azithromycin ring. The alkyl 
linker is flexible and was inspired by a similar group in the ketolide antibiotic 
telithromycin. In contrast, the alkyl aryl group is more rigid and was designed to test the 
effect of such constraint on compound ribosome binding affinity.  Additionally, the 
substitutions on the indole ring were chosen to test the reliance of the interaction of the 
compounds with the ribosome on the A751/W155 π stacking.  The requisite 
azithromycin-indole derivatives were obtained via copper (I) catalyzed azide-alkyne 
cycloaddition.
14
 Expanding upon the observation of the previous peptolide class, the 
incorporation of this selective interaction moiety into N-10 modified, azithromycin-
derived peptolides will furnish a new class of probes which are expected to bind the exit 
tunnel within the L4/L22 constriction section to the egress point at the back of the 50S 
subunit.  We showed that derivatization of the N-10 endocyclic amine of azithromycin 
with moieties which mimicked the SecM W155 side-chain resulted in a sub-set of 
analogs with enhanced translation inhibition activities against E.coli ribosome.  
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3.3 In Vitro Translation Inhibition Assay 
 To characterize the effects of azithromycin N-10 functionalization on ribosome 
function, we analyzed the ability of the all the synthesized compounds to inhibit 
prokaryotic and eukaryotic translation. The prokaryotic ribosome functional assay we 
used is based on the whole cell extract from E. coli, while the eukaryotic assay is derived 
from rabbit reticulocyte lysate (RRL) extract. Both assays utilize a luciferase based 
reporter, which measures the amount of luciferase protein produced, to indirectly 
quantify ribosome function.
11,12
 We determined the IC50s for all the target compounds in 
addition to that of azithromycin which we used as a positive (Table 2).   
We observed that all N-10 functionalized azithromycin compounds retained the 
prokaryotic translation inhibition preference of the parent azithromycin skeleton as none 
inhibits eukaryotic ribosome function up to the maximum tested concentration of 250 M 
(Table 2). All compounds potently inhibit the prokaryotic ribosome function with a sub-
set having enhanced translation inhibition activities relative to the azithromycin positive 
control. For the alkyl-linked series, the attachment of the indole moiety through the C-3 
(compound 19a) weakens translation inhibition activity by 2-fold relative to 
azithromycin. Chloro- and fluoro-substitution at C-5 (compound 20a and 21a 
respectively) further weakens activity with fluorination resulting in the weakest activity 
(9-fold less than azithromycin).   Interestingly, N-1 methylation of the unsubstituted 
indole ring (compound 22a) restores translation inhibition to a level slightly better than 
azithromycin. Connection of the indole to the azithromycin ring through the N-1 position 
further enhanced translation inhibition as the resulting compound 23a is 2.3-fold more 
potent then azithromycin. Although the subsequent C-5 halogenation compromised  
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Table 2:  IC50 and MIC50 data for compounds 19a-28a and 19b-28b.  All indole 
modifications studied are as shown.  S30 = E. coli cell free; RRL = rabbit 
reticulocyte cell free.  SA29213 = S. sureus ATCC 29213 (with serum as indicated). 
Enhancement is calculated as the ratio of MIC50 without serum over that with 
serum. ErmMRSA33591 = Erm
+
 MRSA ATCC 33591. EC27856 = E. coli ATCC 
27856. nt = not tested. 
  Cmpd 
ID 
 IC50 (µM) MIC50 (µg/mL) 





 19a H 0.540 ± 0.056 
 
>250 0.78 0.078 10 NI 16 




0.16 5 NI 32 
21a F 2.6 ± 0.29 
 
>250 0.78 0.16 5 NI 32 
 22a  0.227 ± 0.048 
 
>250 1.56 0.16 10 NI 128 
 23a H 0.128 ± 0.032 
 
>250 1.56 0.16 10 NI 64 
24a Cl 0.490 ± 0.070 
 
>250 0.78 0.16 5 NI 64 
25a F 0.646 ± 0.27 
 
>250 1.56 0.31 5 NI 16 
26a NO2 0.811 ± 0.24 
 
>250 1.56 0.63 2.5 NI 16 
27a OMe 0.238 ± 0.046 
 
>250 1.56 0.16 10 NI 16 
 28a  0.147 ± 0.013 
 






 19b H 0.12 ± 0.11 
 
>250 3.13 1.56 2 NI NI 
20b Cl 0.586 ± 0.065 
 
>250 1.56 1.56 1 NI NI 
21b F 2.03 ± 0.29 
 
>250 3.13 1.56 2 NI NI 
 22b  0.641 ± 0.19 
 
>250 6.25 1.56 4 NI 128 
 23b H 0.197 ± 0.026 
 
>250 1.56 0.63 2.5 NI 64 
24b Cl 1.25 ± 0.41 
 
>250 3.13 1.56 2 NI NI 
25b F 0.463 ± 0.16 
 
>250 1.56 0.78 2 NI 64 
26b NO2 0.442 ± 0.16 
 
>250 1.56 0.39 4 NI 128 
27b OMe 0.504 ± 0.0051 
 
>250 1.56 0.78 2 NI NI 
 28b  0.555 ± 0.045 
 
>250 1.56 0.78 2 NI 64 
 
 29  1.22 ± 0.063 
 
>250 3.13 0.31 10 NI 32 
Azithromycin 
   0.292 ± 0.12 
 
>250 0.78 0.13 6 NI 4 
Chloramphenicol 
   nt nt nt nt  nt 4 
Vancomycin 
   nt nt 1.56 1.56 1 4 nt 
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translation inhibition, fluorination at this position did not result in a glaring deleterious 
effect on potency as seen in the C-3 linked series (Table 2, comparing 20a/21a with 
24a/25a). Introduction of nitro group into the C-5 position further weakens compound 
potency while methoxy group in the same position is less deleterious but the resulting 
compound 27a is about 2-fold less active than the unsubstituted compound 23a. 
Reduction of the indole group to indoline has only a modest effect on compound 
translation inhibition activity (Table 2, comparing 23a and 28a). Compound 29, alkyl-
linked analog lacking the indole moiety, is about 2- to 10-fold weaker translation 
inhibitor than the unsubstituted C-3 and N-1 compounds 19a and 23a respectively. This 
data is suggestive of the essential role the interaction of the indole group with the 
ribosome components, possibly A751, plays in the potency of these N-10 functionalized 
azithromycin compounds.   
 The trend of translation inhibition activities among the more rigid alkylaryl-linked 
compounds 19b-28b is somewhat different from the trend within the flexible alkyl-linked 
compounds 19a-28a. Specifically, the alkylaryl-linked compounds are more tolerant of 
the points of linkage of the indole to the azithromycin as the translation inhibition 
activities of the C-3 and N-1 linked compounds 19b and 23b are virtually 
indistinguishable. Similar to the alkyl-linked compounds, halogenation at C-5 proved not 
to be beneficial. Nevertheless, we noticed an interesting switch of preference for either 
fluoro or chloro-substitution within the N-1 and C-3 linked compounds (Table 2, 
comparing 20b/21b vs 24b/25b).  In contrast to what we observed in the alkyl-linked 
compounds, N-1 methylation of the unsubstituted indole ring worsens translation 
inhibition by more than 5-fold (Table 2, comparing 19b and 22b). Introduction of nitro 
(26b) or methoxy (27b) group into the C-5 position of the N-1 linked analogs has no 
added benefit to potency while reduction of the indole group to indoline surprisingly 
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weakens compound potency by about 3-fold (Table 2, comparing 23b and 28b). 
Collectively, this translation inhibition study revealed that N-1 linked compounds 23a 
and 28a, C-3 linked compounds 19b and 23b are more potent prokaryotic translation 
inhibitors than azithromycin. 
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3.4 Antibacterial Activity 
3.4.1 Protocol 
 Minimum inhibitory concentrations (MIC50) of all compounds was determined 
using liquid microdilution methods.
13
  Briefly, E. coli (ATCC 27856, LB liquid medium), 
S. aureus (ATCC 29213, TSB broth), and methicillin-resistant S. aureus (ATCC 33591, 
Nutrient broth) were grown overnight at 37 
o
C.  These cultures were diluted 1:1000 with 
their respective growth media prior to plating onto TPP 96-well tissue culture plates 
(Sigma, TPP 92096).  Positive controls were as follows: chloramphenicol for E. coli, 
whereas azithromycin and vancomycin for S. aureus and MRSA, respectively.  Cell 
growth was determined by a comparison of OD600 values using a Molecular Devices 
SpectraMax M2 both before and after incubation (18 hrs, 37 
o
C).  All compounds were 
done in triplicate and standardized against an internal vehicle control. 
 Bovine serum (Life Technologies, 16170-086) trials with S. aureus ATCC 29213 
were prepared and analyzed in a similar manner with the only variation being that the 
1:1000 dilution was done with 50% of serum and broth.   
3.4.2 Antibacterial Activity Results 
 To test if these N-10 functionalized azithromycin compounds possess bacterial 
growth inhibition activity, we challenged them with a wild type, macrolide susceptible S. 
aureus (ATCC 29213), macrolide resistant S. aureus (ErmMRSA, ATCC 33591) and 
gram negative (E. coli, EC 27856) bacterial strains. Against E. coli, most of these N-10 
functionalized compounds are weakly active with only 28a performing at a comparative 
level as azithromycin. Against macrolide susceptible S. aureus, we observed that despite 
their enhanced cell-free activities, compounds 19b, 23a, 23b and 28a are no better than 
azithromycin (Table 2). This discrepancy may be due to impairment of cell penetration of 
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the N-10 functionalized compounds. However, the compounds within the alkyl-linked 
series (19a-28a) are slightly more potent than their alkylaryl-linked counterparts (19b-
28b).  Relative to 29, the antibacterial activity of compounds 19a and 23a is about 2-fold 
enhanced, further supporting the role of the indole moiety in the interaction of these 
azithromycin analogs with the ribosome. 
 Interestingly, inclusion of 50% bovine serum into the culture media resulted in 
moderate (24b, 25b) to 10-fold (19a, 22a, 27a, 28a) enhancement of the antibacterial 
activities of these N-10 functionalized azithromycin compounds. In comparison, 
azithromycin displayed a 6-fold potency enhancement in 50% bovine serum media. A 
similar serum-induced potency enhancement has been observed with azithromycin and 
other macrolides.  This has been shown to be immune response independent, however pH 
and cell wall morphology disruption could play a role.
10  
Neither azithromycin nor any of 
these N-10 modified compounds are active against S. aureus with constitutively active 
ermA (Erm
+
MRSA, ATCC33591), a macrolide resistant mechanism which targets the 




 The ribosomal peptide exit tunnel is an inviting site for drug design. We have 
disclosed a set of functionalized azithromycin analogs incorporating an indole moiety at 
the N-10 position of the macrolactone ring. The indole moiety of these compounds is 
designed to mimic the translation stalling -stack interaction of SecM W155 side-chain 
with the prokaryotic ribosome A751 residue. Our data revealed that many of these N-10 
functionalized compounds have enhanced translation inhibition activities against E.coli 
ribosome relative to azithromycin, possibly due to proper presentation of the indole 
moiety for stacking interaction with A751. However, despite their enhanced cell-free 
activities, a subset of these compounds inhibited the growth of representative susceptible 
bacteria strains to about the same extent as azithromycin. Additionally, none of these 
compounds was able to overcome ermA-mediated macrolide resistance. This suggests 
that the extra indole-A751 -stacking isn’t sufficient to overcome resistance. While they 
were unable to overcome this resistance, the indole-A751 -stacking could pre-set the 
orientations of peptolides bearing this moiety such that they bind the exit tunnel within 
the L4/L22 constriction section to the egress point at the back of the 50S subunit.   
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CHAPTER 4  Redesign of Conjugate Probes to Improve Cell 
Membrane Activity  
4.1 Introduction 
 While working to incorporate a means of directing a peptide probe through the 
A751-W155 pi stack discussed within Chapter 3 of this document, an interesting question 
came about.  Should the pi stack interaction be successfully engaged, would this added 
interaction provide enough stability to counteract the lost interaction brought about by 
erm methylation?  While evaluation of whole cell viability of probes 19-28 showed that 
none within the series were active against a cell line with this resistance, we could not 
discount the possibility of other resistance phenotypes contributing to the loss of activity.  
This observation served as a start for a larger evaluation of how our full array of 
conjugate probes performs against whole cells.  The telithromycin and azithromycin 
series certainly showed potent cell-free translation inhibition activity with the overall best 
in the respective series showing activity as good as, if not better, than the parent 
compounds.  With the successful inhibition of whole cell growth in a quality control S. 
aureus line (ATCC 29213) by the azithromycin-tryptophan conjugates, we decided to 
revisit a more broad range of probes within various anchor classes to investigate their 
performance as inhibitors of cell growth. 
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4.2 Whole Cell Activity of Linezolid-Inspired Anchors 
 The linezolid probes discussed within Chapter 2.3 were challenged in the same 
quality control S. aureus (ATCC 29213) used in Chapter 3.  All within this series 
displayed no inhibition up to a maximum tested dose of 64 µg/mL (Figure 33) even 
though the parent linezolid, trade name Zyvox, displayed activity within the Clinical and 
Laboratory Standards Institute (CLSI) accepted experimental range.  As a result of no 
activity within the QC line, they were not carried through to the methicillin resistant S. 
aureus (MRSA, ATCC 33591) cell line. 
             
Figure 33:  Structures and MIC50s of linezolid-inspired conjugates.  Values 
determined in S. aureus QC cell line (ATCC 29213).  
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4.3 Whole Cell Activity of Azithromycin-Inspired Anchors  
 Concurrent with the synthesis of the azithromycin-tryptophan conjugates, 
azithromycin-peptide probes were developed and synthesized.  The rational design was 
borne of the same thinking as the tryptophan series: modification about azithromycin’s 
N10 of the macrolactone would project the probe of interest more exclusively down the 
tunnel by restricting the opportunity to align back toward the PTC.  These conjugates 
(synthesized by Dr. Subhasish Tapadar) contained a peptide sequence very similar to the 
central aromatic core of peptolides 12e/f.  While these all possessed rather potent cell-
free translation inhibition, none within the series displayed any whole cell inhibition 
activity (Figure 34). 
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Figure 34:  Structures and MIC50s of azithromycin-inspired conjugates.  Values 
determined in S. aureus QC cell line (ATCC 29213) and MRSA resistance strain 
(ATCC 33591).  
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4.4 Whole Cell Activity of Telithromycin-Inspired Anchors 
 The original peptolide series, as described in Chapter 2.4, was also analyzed for 
whole cell activity.  It had also expanded to include additional peptide sequences, all 
containing the butyl linker.  This linker, as opposed to the propyl linker also used, is more 
directly comparable to the telithromycin parent as well as showing consistently better 
translation inhibition in a cell-free system.  This newest subset of conjugates, while even 
showing improved activity over telithromycin in cell-free trials, displayed no activity 
against S. aureus 29213 (Figure 35) 
             
Figure 35:  Structures and MIC50s of second generation telithromycin-inspired 
conjugates.  Values determined in S. aureus QC cell line (ATCC 29213) and MRSA 
resistance strain (ATCC 33591).  
 
 Within the original peptolide series, a similar trend was seen where there was no 
activity for most.  The peptolide 12b of biologically appropriate peptide backbone with 
the greatest cationic nature and butyl linker displayed activity at 149.00 ± 3.65 µg/mL.  
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While this value suggests very weak antibacterial activity, it provided a direction and 
possibility.  In analyzing the potential cause for activity, cell permeability seemed the 
best starting approach, however alternative possibilities for low activity were believed to 
be resistance mechanisms such as active efflux or enzymatic degradation of the 
conjugate.  With data showing that the parent compounds and, in some cases, the 
synthetic intermediates retained whole cell growth inhibition, we focused out attention on 
improving the profile of our peptide.   
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4.5 Replacement of the Peptide Moiety for Peptidiomimetic Peptoids 
 We first considered the use of naturally occurring antimicrobial peptides.  These 
are translated by an organism as a defense peptide, are relatively short (less than 100 
amino acids), and highly cationic and amphipathic.
1
  This last inclusion greatly bolsters 
the ability of these small peptides to penetrate the cell wall by aligning the R-groups of 
the amino acids in such a way that all hydrophobic moieties are able to bore into the cell 
wall while hydrophilic ones can maintain a favorable interaction with the surrounding 
solvent.  These peptides, however, tend to be very short-lived and highly susceptible to 
enzymatic hydrolysis.  This can be mitigated by shifting the R-group identity off of the α-
carbon and onto the amide nitrogen (Figure 36).  This peptidomimetic structure, dubbed 
peptoid, have been used extensively as antimicrobials, molecular transporters, anticancer 
agents, and even nanostructured materials.
1-4
   
 Dr. Jainfend Cai of University of South Florida has extensive experience with 
membrane active peptides and peptoids.  In seeking sequences to explore, a collaboration 
was established.  As an initial trial and potential proof of concept, we were provided with 
an alkynyl version of a peptoid.  This peptoid, seen in Figure 4.5, was derived from a 
sequence with very weak bacterial membrane penetration activity.
5
  In agreement with 
their findings and our experience with testing uncoupled peptide sequences, it displayed 
no activity when tested in either our cell-free translation inhibition ( > 250 µM) or the 
whole cell growth inhibition ( > 256 µg/mL) assays.  While not identical sequences, this 
newly obtained peptiod (Figure 37, 33) is very similar to the sequence found on the 
peptolide that displayed whole cell activity inasmuch as maintaining a central core that is 
highly cationic; +5 for both sequences.  
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Figure 36:  Standard Peptides and Peptoids.  Left Peptide formed from natural L-
form amino acids where the amino acid identifiers, denoted as R
n
, are bound to the 
α-carbon.  Right Characteristic peptoid backbone where the side group has been 
shifted from the α-carbon onto the amide nitrogen.  Figure adapted from [14]. 
 
 We proceeded to couple the peptoid sequence to the same telithromycin-azide 
anchor (synthesis performed by Dr. Subhasish Tapadar).  In cell free translation 
inhibition, peptoid peptolide 32 inhibits prokaryotic translation with potency that is 
approximately five-fold weaker than the corresponding peptide ketolide 14b (Figure 37).  
 This suggests that there is a possibility that the subtle structural changes about the 












Table 3:  Peptoid conjugate activity.  Peptide-ketolide (“peptolide”) conjugate 14b 
was the only peptide conjugate to display whole cell activity.  Peptoid-ketolide 
conjugate retained similar cell free IC50 values, however improved whole cell 
activity by 3-fold compared to peptolide 14b.  Unconjugated peptoid 21 displays no 
activity.   
 
  E. coli IC50 (µM) Rabbit Retic. IC50 (µM) S. aureus MIC50 (µg/mL) 
14b 0.67 ± 0.28 >250 149.00 ± 3.65 
32 3.34 ± 0.54 >250 47.08 ± 4.81 
33 >250 >250 >256 
  
 With validation that the peptoid conjugate retains translation inhibition activity, 
we compared the effect of the peptoid conjugate on whole cell activity against that of the 
peptolide probe.  Despite the reduced cell free performance of 32, we observed a potent 
enhancement of whole cell activity relative to 14b.  We believe that the replacement of 
the peptide for the peptoid results in additional membrane activity.  This disruption 
contributes to a three-fold enhancement of whole cell activity over the peptide 
counterpart (Table 3).   This is an incredibly exciting result as it suggests that the peptoid 
is capable of increased cell membrane penetration while ferrying in the ketolide 
antibiotic.      
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Figure 37:  Peptoid Conjugate.  Alkyne peptoid provided by the Cai lab in 
University of South Florida. 
 
4.6 Discussion 
 The transition to a peptoid sequence is an interesting prospect.  We observed that 
the peptoid conjugate 32 has prokaryotic cell free translation inhibition activity that is 
approximately five-fold less than the corresponding peptide conjugate 14b, however 
displays improved whole cellactivity.  As previously stated, it is believed at this point that 
this is due to enhanced cell membrane penetration activity afforded by the peptoid moiety 
while the tethered ketolide is responsible for maintaining translation inhibition activity.  
The collaboration with the Cai lab will continue as we explore the applications of this 
further.  Additional conjugates will be made by first varying the peptoid in both R-groups 
as well as length, but also the anchor region may be altered to explore different 
possibilities of activity in both whole cell as well as cell free assays.  As a probe, the 
varied backbone of the peptoid could provide an alternative window with perhaps more 
opportunity for variation about the R group identities.  Collectively, this new avenue 
could offer a substantial opportunity for new exploration of therapeutic improvement as 
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CHAPTER 5  CONCLUSIONS AND FUTURE DIRECTIONS  
 The study described in this thesis provides a foundation fundamental to the design 
of future probe conjugates capable of analyzing the nature and extent of interactions 
between a nascent peptide and the ribosomal exit tunnel.  The possibility exists where 
sites of dynamic interaction within the tunnel may be used to design novel sets of 
compound classes capable of serving as antibiotics (prokaryotes) and anticancer agents 
(eukaryotes).  We have demonstrated that the conjugate probe design is a viable approach 
affording the capability to biochemically evaluate retention of anchor function as well as 
crystallographically visualize atomic level interactions.  Within the context of a synthetic 
probe not reliant on active translation, we are the first to show probe dependent 
conformational change of multiple residues lining the prokaryotic ribosomal exit tunnel.  
These changes are made up of both likely hydrogen bond interactions as well as steric 
repulsion.  By taking a cue from nature, we have developed the approach to engage in the 
known critical interaction of 23S A751: SecM W155 to encourage a selective path of 
travel down the exit tunnel for future probe designs.  Additionally, we are expanding our 
pool of peptide sequences to include peptidomimetics.  The coupling of more cell 
membrane active peptoids to our antibiotic anchors is currently being pursued.  Finally, 
by continuing to look at nature for peptide sequence inspiration, the Oyelere lab will 
work to incorporate newer models.  One such class of peptide is the “proline-rich 
antimicrobial peptide” (PrAMPs).  Many of these have a very high representation of not 
just proline, but also arginine.  This inclusion of proline as well as basic residues is 
reminiscent of the peptide sequences of probes 14a-14d, probes responsible for very 
potent cell free translation inhibition and probe dependent interactions within the exit 
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tunnel shown by crystallography.  While it had been previously shown that they have an 
ability to halt translation, recent crystal structures have shown their orientation within the 
PTC and exit tunnel.  In overlaying crystal structures, an approach will be planned to 
utilize these PrAMPs as next generation of peptides to be explored for probe design.  
 
Figure 38:  PrAMP overlay.  PrAMP “Onc112” (Yellow, PDB 4ZER) and 
telithromycin (Purple, PDB 3OI3).  PTC lies to the left of the image.  Final proline 
directly overlays with the butyl linker of telithromycin. 
 
Overlaying telithromycin (Figure 38) displays the alignment of the PrAMP to the alkyl-
aryl arm.  By modifying telithromycin in a manner similar to that of the peptolide probes 
discussed in Chapter 2.4, conjugation becomes achievable affording a series with peptide 
sequence specific stalling capability. 
 The variability in both the anchors and the peptides offers very exciting 
opportunities to truly explore the extent of nascent peptide-ribosomal exit tunnel 







A.1. Chapter 2 Supplemental 










Elemental Composition Report 
 
Single Mass Analysis (displaying only valid results) 
Tolerance = 6.0 PPM   /   DBE: min = -1.5, max = 200.0 
Selected filters: None 
 
Monoisotopic Mass, Odd and Even Electron Ions 
117 formula(e) evaluated with 2 results within limits (all results (up to 1000) for each 
mass) 
Elements Used: 
C: 0-500    H: 0-1000    N: 5-9    O: 2-6     
Minimum:                                        -1.5 
Maximum:                    5.0       6.0       200.0 
Mass         Calc. Mass      mDa      PPM      DBE       Formula 
428.2024    428.2046        -2.2      -5.1          11.5      C20  H26  N7  O4  
















A.2. Collaboration with Dr. Dev Arya of Clemson University 
A.2.1. Introduction 
 The following data was published as part of a collaboration with Clemson 
University and the lab of Dr. Dev Arya.   My contribution to the manuscript was 
using the cell-free translation inhibition assay to validate a single-dose IC50 
determination of 12 neomycin-amino acid conjugates and 2 positive controls.  Both 
eukaryotic and prokaryotic assays were utilized.  
 
A.2.2. Manuscript Citation 
Jiang, L., Watkins, D., Jin, Y., Gong, C., King, A., Washington, A. Z., Green, K. D., 
Garneau-Tsodikova, S., Oyelere, A. K. and Arya, D. P. (2015) Rapid synthesis, RNA 
binding, and antibacterial screening of a peptidic-aminosugar (PA) library. ACS Chem 
Biol 10, 1278-1289. 
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A.2.3. Full data contribution 
A.2.3.1. Prokaryotic Assay Results 
Abbreviation 
Structures of free amine state. All 
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A.2.3.2. Eukaryotic Assay Results 
Abbreviation 
Structures of free amine state. All 
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